Polycystic kidney disease is a genetic disorder characterized by the progressive development of multiple fluid-filled cysts in the kidneys, leading to renal enlargement and eventual loss of kidney function.

Exam domain	One-glance essentials
Definition / diagnosis	ADPKD is an autosomal-dominant ciliopathy causing progressive bilateral renal and extrarenal cysts. ^[1] It is the most common inherited kidney disease and a major cause of ESRD. ^[1]
Epidemiology / risks	Each child of an affected parent has a 50% inheritance risk. ^[1] PKD1 generally causes earlier ESRD than PKD2. ^[1] Hypertension, smoking, obesity and high salt intake worsen renal or cardiovascular risk. ^[1]
Core mechanism	Dysfunctional polycystin-1/2 signalling increases intracellular cAMP, promoting tubular-cell proliferation and fluid secretion. ^[1] A germline mutation plus somatic second hit produces focal cyst formation, followed by nephron compression and fibrosis. ^[1] Cyst-related vascular compression activates intrarenal RAAS, causing early hypertension. ^[1]
Clinical picture	Typical features: hypertension, haematuria, flank pain, recurrent UTI, stones, polyuria/nocturia and bilateral enlarged kidneys. ^[1] Hepatic cysts are the commonest extrarenal manifestation; liver function is usually preserved. ^[1] Thunderclap headache or a painful third-nerve palsy suggests aneurysmal SAH. ^[1]
Investigations	Renal ultrasound is first-line; bilateral cysts with enlarged kidneys support ADPKD, especially with a positive family history. ^[1] MRI/CT is more sensitive for small cysts and MRI measures total kidney volume for progression risk. ^[1] Use genetic testing for equivocal imaging, very young individuals or potential donors; heavy proteinuria suggests superimposed glomerulopathy. ^[1] MRA/CTA evaluates intracranial aneurysm in high-risk patients. ^[1]
Management	Control BP, usually with an ACE inhibitor or ARB; restrict sodium and maintain appropriate fluid intake. ^[1] Tolvaptan slows cyst and renal-function progression in selected rapidly progressive disease; monitor for polyuria and hepatotoxicity. ^[1] Cyst infection requires lipid-soluble antibiotics for 4–6 weeks; drain refractory infected cysts. ^[1] ESRD management includes dialysis planning; transplantation is the preferred definitive treatment. ^[1]
Complications	Major complications include progressive CKD/ESRD, cyst haemorrhage, recurrent infection and nephrolithiasis. ^[1] Intracranial aneurysm rupture causing SAH is the most serious complication; cardiovascular disease is a major cause of death. ^[1] Cyst infection may have a negative urine culture when the cyst does not communicate with the collecting system. ^[1]
Prevention / follow-up	Reduce sodium, avoid smoking, control weight and BP, and avoid abdominal trauma when kidneys are very large. ^[1] Offer aneurysm screening with MRA/CTA to high-risk patients, particularly those with a family history of aneurysm or SAH. ^[1] Monitor eGFR, BP, kidney volume and treatment toxicity; provide genetic counselling before family planning or kidney donation. ^[1]
Exam traps	Normal renal function does not exclude ADPKD; GFR may remain preserved until later disease. ^[1] Heavy proteinuria is atypical—look for an additional glomerular disorder. ^[1] Do not confuse ADPKD with acquired cystic kidney disease: dialysis-associated kidneys are small/normal-sized and lack extrarenal features. ^[1] ARPKD presents early and is linked to PKHD1 and congenital hepatic fibrosis. ^[1]

References

^[1] Senior notes: felixlai.md (Polycystic kidney disease section)

Polycystic Kidney Disease (PKD)

Polycystic Kidney Disease (PKD) refers to a group of inherited disorders characterised by the progressive development of multiple fluid-filled, epithelial-lined cysts within the renal parenchyma, leading to massive bilateral kidney enlargement and eventual loss of renal function. The name itself tells you the condition: "poly" = many, "cystic" = cysts (fluid-filled sacs), "kidney disease."

There are two major forms:

Autosomal Dominant Polycystic Kidney Disease (ADPKD) — the "adult" form, the overwhelmingly more common type
Autosomal Recessive Polycystic Kidney Disease (ARPKD) — the "infantile" form, rare but severe

These are fundamentally different diseases at the genetic, pathological, and clinical level — they just happen to share the feature of renal cysts. Throughout these notes, the primary focus is on ADPKD unless otherwise stated, as it is the one you will encounter in clinical practice and exams far more frequently.

Key Conceptual Point

PKD is NOT the same as having "multiple simple renal cysts." Simple cysts are acquired, increase with age, and are benign. PKD is a genetic, progressive, systemic disorder with extrarenal manifestations. The distinction matters enormously for prognosis and management.

2. Epidemiology

Incidence: approximately 1 in 400 to 1 in 1,000 live births ^[1]
Most common inherited kidney disease and the 4th leading cause of end-stage renal disease (ESRD) worldwide
Accounts for approximately 5–10% of all patients on renal replacement therapy (RRT) globally
No racial predilection — occurs equally across all ethnic groups
Affects males and females equally (autosomal dominant inheritance — not sex-linked)
Median age at ESRD: ~54 years for PKD1 mutations, ~74 years for PKD2 mutations ^[1]
In Hong Kong, PKD is listed among the congenital/inherited causes of CKD, accounting for approximately 5% of CKD cases ^[2]
Cerebral aneurysms are found in 2–5% of the adult population but are significantly more prevalent in ADPKD patients (approximately 8–12%) ^[3]

Incidence: approximately 1 in 20,000 live births ^[1]
Carrier frequency ~1 in 70
Presents in the perinatal/neonatal period or childhood
Significant perinatal mortality (up to 30–50%) due to pulmonary hypoplasia from oligohydramnios

High Yield: ADPKD is one of the most common monogenic (single-gene) disorders in humans. It is more common than sickle cell disease, cystic fibrosis, haemophilia, and Down syndrome combined.

Since PKD is a genetic disease, the primary "risk factor" is having the mutation. However, several factors influence disease severity and rate of progression:

Factor	Effect on Progression	Mechanism
PKD1 mutation (vs PKD2)	Earlier onset ESRD (~54 vs ~74 years)	PKD1 produces more severe cystogenesis due to greater loss of functional polycystin-1
Truncating PKD1 mutation (vs non-truncating)	Worse prognosis	Complete loss of polycystin-1 function
Male sex	Slightly faster progression	Possible hormonal influence (androgens may promote cyst growth)
Hypertension	Accelerates CKD progression	Activates RAAS → further cyst growth + renal fibrosis
Large kidney volume (TKV)	Predictor of future GFR decline	Directly reflects cyst burden
Gross haematuria before age 30	Worse prognosis	Reflects more aggressive cystogenesis
Proteinuria	Worse prognosis	Indicates more advanced parenchymal damage
Early onset of symptoms	Worse prognosis	Reflects more aggressive disease
Family history of early ESRD	Increased risk	Shared genetic modifier effects
High salt intake, caffeine	May accelerate cyst growth	cAMP stimulation (caffeine), volume expansion (salt)
*Smoking, obesity, hypertension*	Also risk factors for associated complications such as RCC and CVD	General cardiovascular risk factors that compound PKD morbidity ^[4]^[5]

Exam Pearl

The single most important prognostic factor in ADPKD is the genotype: PKD1 truncating > PKD1 non-truncating > PKD2. The second most important measurable predictor of progression is total kidney volume (TKV) on MRI.

4. Anatomy and Function (Relevant Normal Kidney Anatomy)

To understand PKD, you need to understand what cysts are replacing.

Each kidney contains approximately 1 million nephrons
Each nephron consists of:
- Glomerulus (filtration)
- Proximal convoluted tubule (reabsorption of ~65% filtrate, glucose, amino acids, bicarbonate, phosphate)
- Loop of Henle (countercurrent mechanism, concentration/dilution)
- Distal convoluted tubule (fine-tuning of Na⁺, K⁺, Ca²⁺)
- Collecting duct (final concentration via ADH, acid-base via intercalated cells)
Renal blood supply: renal artery → segmental → interlobar → arcuate → interlobular → afferent arteriole → glomerulus → efferent arteriole → peritubular capillaries/vasa recta

In ADPKD, cysts arise from all segments of the nephron (glomerulus through collecting duct). Only about 1–5% of nephrons develop cysts, but these cysts expand progressively and compress surrounding normal parenchyma.
In ARPKD, cysts arise specifically from the collecting ducts — they are characteristically fusiform (spindle-shaped) dilatations of the collecting ducts, giving a radial/medullary ray pattern on imaging.

ADPKD is a systemic ciliopathy — the proteins involved (polycystin-1 and polycystin-2) are expressed in:

Bile ducts → hepatic cysts
Pancreatic ducts → pancreatic cysts
Seminal vesicles → seminal vesicle cysts
Arachnoid membrane → arachnoid cysts
Arterial walls → cerebral aneurysms ^[3]
Cardiac valves → mitral valve prolapse
Colonic wall → colonic diverticula

5. Etiology and Pathophysiology

5.1 Genetic Basis

Gene	Chromosome	Protein	Frequency	Phenotype Severity
PKD1	Chromosome 16p13.3	Polycystin-1 (PC1)	~85% of ADPKD	More severe; ESRD ~54y
PKD2	Chromosome 4q21	Polycystin-2 (PC2)	~15% of ADPKD	Less severe; ESRD ~74y
GANAB / DNAJB11	Various	Glucosidase IIα / HSP40 co-chaperone	Rare (< 1%)	Milder phenotype

^[1]^[2]

Inheritance is autosomal dominant — each child of an affected parent has a 50% chance of inheriting the disease
However, ~10% of cases are de novo mutations (no family history)
Disease expression follows the "two-hit" hypothesis (Knudson's model, similar to retinoblastoma):
- Every cell has one normal allele and one mutant allele (the germline mutation)
- Cyst formation requires a second somatic "hit" (loss or mutation of the remaining normal allele) in individual tubular epithelial cells
- This explains why only 1–5% of nephrons develop cysts despite every cell carrying the germline mutation
- It also explains the variability in cyst distribution and the focal nature of cyst development

Why PKD1 is worse than PKD2

Think of it this way: Polycystin-1 is the larger, more critical signaling molecule. With PKD1 mutations, the threshold for the "second hit" is lower (the remaining normal allele needs less damage to lose function), so more nephrons develop cysts earlier. PKD2 patients have a higher threshold, so they develop fewer cysts, later.

Gene	Chromosome	Protein	Feature
PKHD1	Chromosome 6p12	Fibrocystin / Polyductin	Expressed in collecting ducts and biliary epithelium

^[1]

Both alleles must be mutated → much rarer
The severity of ARPKD depends on the nature of the mutations:
- Two truncating mutations → usually lethal in utero or neonatal period
- At least one missense mutation → milder phenotype, may survive to childhood/adolescence
Always associated with congenital hepatic fibrosis (ductal plate malformation)

5.2 Pathophysiology — The Ciliopathy Model

This is the crucial concept. ADPKD is a ciliopathy — a disease of the primary cilium.

A non-motile, antenna-like structure projecting from the apical surface of almost every cell, including renal tubular epithelial cells
It acts as a mechanosensor — detecting fluid flow in the tubular lumen
When urine flows over the cilium, it bends → triggers an influx of Ca²⁺ into the cell via the polycystin-1/polycystin-2 complex

Polycystin-1 (PC1): a large transmembrane protein that acts as a mechanoreceptor on the primary cilium. It senses fluid flow and transduces the signal.
Polycystin-2 (PC2): a calcium-permeable cation channel (a member of the TRP channel family — Transient Receptor Potential). It is the effector that allows Ca²⁺ to enter the cell when PC1 is activated.
Together, they form a receptor-channel complex on the primary cilium.

The key downstream consequences of dysfunctional polycystins are:

↓ Intracellular Ca²⁺ → loss of the inhibitory brake on cAMP
↑ cAMP (cyclic AMP) → the central driver of cystogenesis:
- Stimulates fluid secretion via CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) chloride channels on the apical membrane → Cl⁻ secretion into the cyst lumen → Na⁺ and water follow osmotically → cyst expansion
- Stimulates cell proliferation via the Ras/MAPK and mTOR pathways → cyst wall growth
Altered cell polarity — the Na⁺/K⁺-ATPase is mislocalized to the apical surface (normally basolateral) → further drives fluid secretion into the cyst
Abnormal extracellular matrix remodeling → fibrosis of surrounding tissue

Why Tolvaptan Works — The cAMP Connection

Tolvaptan is a vasopressin V2-receptor antagonist. In renal collecting duct cells, ADH (vasopressin) binds V2 receptors → activates adenylyl cyclase → ↑cAMP. In PKD, this cAMP drives cyst growth. By blocking V2 receptors, tolvaptan reduces cAMP in collecting duct cells → slows cyst growth and fluid secretion. This is the basis of its use as the only approved disease-modifying therapy for ADPKD.

Once cysts form, they undergo progressive, relentless expansion:

Cysts enlarge at an average rate of ~5% per year in total kidney volume (TKV)
Cysts compress adjacent normal nephrons → ischaemia, atrophy, and interstitial fibrosis
Renal function (GFR) is maintained for a remarkably long time because the remaining nephrons undergo compensatory hyperfiltration
GFR typically remains normal until kidney volume exceeds ~1500 mL (normal ≈ 150–200 mL per kidney)
Once GFR starts declining, it drops at approximately 4.4–5.9 mL/min/year

This gives rise to the characteristic clinical pattern: years of preserved GFR → then relatively rapid decline → ESRD

Hypertension occurs in ~60% of ADPKD patients before any decline in GFR — this is a crucial distinguishing feature from other CKD causes where hypertension is a late feature.

The mechanism is intrarenal RAAS activation:

Expanding cysts compress adjacent renal vasculature → regional ischaemia
Ischaemic juxtaglomerular cells sense ↓perfusion → secrete renin
Renin → angiotensinogen → angiotensin I → angiotensin II → vasoconstriction + aldosterone secretion → sodium and water retention → hypertension
This is essentially a form of "intrarenal renal artery stenosis" — multiple small areas of ischaemia from cyst compression

Because polycystin-1 and polycystin-2 are expressed ubiquitously, ADPKD is truly a systemic disease:

Extrarenal Manifestation	Prevalence	Mechanism
Hepatic cysts	83% by age 30-40; most common extrarenal manifestation	Same ciliopathy mechanism in bile duct epithelium; estrogen-dependent (more common/severe in women, especially multiparous)
Pancreatic cysts	~5–10%	Ciliopathy in pancreatic duct epithelium
Seminal vesicle cysts	~40% of males	Ciliopathy in seminal vesicle epithelium → may contribute to infertility
*Cerebral (intracranial) aneurysms*	*~8–12% (vs 2–5% general population)*	Defective polycystin in arterial wall smooth muscle → weakness of vessel wall, especially at bifurcations of the Circle of Willis ^[3]
Mitral valve prolapse	~25%	Defective connective tissue in valve leaflets
Aortic root dilatation	~8%	Connective tissue abnormality in aortic root
Colonic diverticula	Increased prevalence	Connective tissue weakness in colonic wall
Abdominal wall and inguinal hernias	Increased prevalence	Connective tissue weakness

6. Classification

Feature	ADPKD	ARPKD
Inheritance	Autosomal dominant	Autosomal recessive
Gene(s)	PKD1 (85%), PKD2 (15%)	PKHD1
Protein	Polycystin-1, Polycystin-2	Fibrocystin/Polyductin
Chromosome	16p13.3, 4q21	6p12
Age of presentation	Usually 30–50 years	Perinatal/neonatal/childhood
Cyst origin	All nephron segments	Collecting ducts only
Cyst morphology	Spherical, variable size (mm to > 10 cm)	Fusiform, small, uniform; radial medullary ray pattern
Kidney size	Massively enlarged (may reach > 3 kg each)	Enlarged but smoother contour
Liver involvement	Hepatic cysts (very common)	Congenital hepatic fibrosis (invariable) → portal hypertension, cholangitis
Other associations	Cerebral aneurysm, MVP, colonic diverticula	Pulmonary hypoplasia (if severe, from oligohydramnios)
Prognosis	ESRD in 50s–70s depending on genotype	Many die in perinatal period; survivors develop portal HTN and CKD

	PKD1	PKD2
Proportion	~85%	~15%
Mean age at diagnosis	30–35 years	45–50 years
Mean age at ESRD	~54 years	~74 years
Mean number of cysts at diagnosis	More	Fewer
Severity of hypertension	Earlier onset	Later onset
Risk of cerebral aneurysm	Similar	Similar

The Mayo Imaging Classification uses height-adjusted total kidney volume (htTKV) on MRI to classify ADPKD patients into risk categories (Classes 1A–1E):

Class	htTKV growth rate (%/year)	Risk of GFR decline
1A	< 1.5%	Low
1B	1.5–3.0%	Low-intermediate
1C	3.0–4.5%	Intermediate
1D	4.5–6.0%	High
1E	> 6.0%	Very high

High Yield: Tolvaptan is indicated for patients with rapidly progressive disease (typically Mayo Class 1C–1E, or evidence of rapid GFR decline). The Mayo classification helps identify who will benefit most.

7. Clinical Features

7.1 Symptoms

The clinical features of ADPKD are dominated by the consequences of progressive cyst enlargement and extrarenal manifestations. Most patients are asymptomatic until age 30–50.

Symptom	Pathophysiological Basis
Flank/loin pain or abdominal heaviness	Progressive cyst enlargement stretches the renal capsule (richly innervated). Large kidneys may cause a dragging sensation. Pain can also be from cyst haemorrhage or infection.
Acute severe flank pain	Cyst haemorrhage (sudden expansion of cyst stretches capsule) or cyst rupture (blood/fluid irritating perinephric tissue). Also consider renal stones.
Gross haematuria	Cyst haemorrhage rupturing into the collecting system; or passage of renal stones; or UTI. Occurs in ~42–50% of patients at some point.
*Polyuria, nocturia, urinary frequency, increased thirst* ^[1]	Early concentrating defect — expanding cysts disrupt the medullary architecture needed for the countercurrent concentrating mechanism (Loop of Henle and vasa recta are compressed). The kidneys lose the ability to concentrate urine → obligatory water loss → nephrogenic diabetes insipidus-like picture → compensatory polydipsia.
Renal colic	Nephrolithiasis — stones occur in ~20–30% of ADPKD patients. Two mechanisms: (1) urinary stasis in distorted collecting system; (2) low urinary citrate and low urinary pH (metabolic disturbances from tubular dysfunction). Most stones are uric acid or calcium oxalate.
Recurrent UTIs	Urinary stasis in distorted collecting system + cyst fluid is an excellent culture medium. Cyst infections (particularly in females) are a major source of morbidity.
Early satiety, abdominal distension	Massive renal (and hepatic) enlargement compresses the stomach and intestines → early satiety, bloating, and sometimes gastro-oesophageal reflux.

Symptom	Pathophysiological Basis
Thunderclap headache	*Subarachnoid haemorrhage (SAH) from rupture of a cerebral (intracranial) aneurysm* — ADPKD patients have ~5× the risk. Aneurysms are typically at the Circle of Willis, especially the anterior circulation (90%) ^[3].
Chronic headache	May relate to unruptured intracranial aneurysm (mass effect), but also hypertension is very common and can cause headache.
Right upper quadrant pain/discomfort	Hepatic cysts — especially in women (estrogen-dependent); massive hepatic cyst burden can cause mechanical symptoms.
Recurrent cholangitis (more in ARPKD)	In ARPKD, biliary dysgenesis and congenital hepatic fibrosis predispose to ascending cholangitis.
Chest pain, palpitations	Mitral valve prolapse (~25%) → may cause atypical chest pain or palpitations from associated mitral regurgitation or arrhythmia.

As renal function declines, standard uraemic symptoms develop:

Fatigue, malaise, anorexia, nausea, vomiting
Pruritus (phosphate retention)
Peripheral oedema, breathlessness (fluid overload)
Muscle cramps, restless legs
Cognitive impairment, confusion (uraemic encephalopathy in severe cases)

7.2 Signs

Sign	Pathophysiological Basis
Hypertension (often the first clinical abnormality)	Intrarenal RAAS activation from cyst compression of renal vasculature → renin secretion → angiotensin II → vasoconstriction and aldosterone-mediated Na⁺/water retention. Present in ~60% before any GFR decline.
Pallor	Anaemia of CKD (↓erythropoietin production from destroyed renal interstitial cells). Note: ADPKD patients tend to have less severe anaemia than other CKD patients at the same GFR, because the cyst lining cells retain some EPO-producing capability.

Sign	Pathophysiological Basis
*Bilateral palpable, enlarged kidneys* ^[6]	Progressive cyst growth → kidneys may reach 20–40 cm in length (normal ~10–12 cm) and weigh up to 3–8 kg each (normal ~150 g). Kidneys are ballotable, have an irregular (bosselated/lobulated) surface, and are bimanually palpable.
Hepatomegaly	*Polycystic liver* — hepatic cysts are the most common extrarenal manifestation ^[6]. Liver may also have an irregular/bosselated surface. Liver function is usually preserved (unlike ARPKD where congenital hepatic fibrosis causes portal hypertension).
Abdominal distension	Massively enlarged kidneys ± hepatomegaly ± ascites (if nephrotic range proteinuria or portal HTN in ARPKD). ^[6]
Loin tenderness	Cyst infection, cyst haemorrhage, or renal calculi.
Costovertebral angle tenderness	Pyelonephritis superimposed on structural abnormality.

Physical Examination Pearl

On abdominal examination of a patient with bilateral palpable kidneys, the differential diagnosis is limited. The most common cause of bilaterally palpable kidneys in an adult is ADPKD. Other causes include bilateral hydronephrosis, bilateral RCC (extremely rare), amyloidosis, lymphomatous infiltration, and diabetic nephropathy (early stages with hyperfiltration) ^[6].

Sign	Pathophysiological Basis
Elevated blood pressure	As above — RAAS activation.
Mid-systolic click ± late systolic murmur	Mitral valve prolapse — defective polycystin in valve connective tissue → myxomatous degeneration → leaflet prolapse during systole.
Aortic regurgitation murmur (rare)	Aortic root dilatation from connective tissue abnormality.
Signs of left ventricular hypertrophy	Chronic hypertension → pressure overload → concentric LVH (sustained apical impulse, S4 gallop).

Sign	Pathophysiological Basis
Inguinal or abdominal wall hernias	Connective tissue defect + chronic increased intra-abdominal pressure from massive kidney/liver enlargement.
AV fistula or Tenckhoff catheter	Evidence of renal replacement therapy if the patient has progressed to ESRD ^[6].
Transplant scar in iliac fossa	Post-renal transplantation ^[6].
Peripheral oedema	Fluid retention from CKD (late); or nephrotic syndrome (uncommon in PKD).
Signs of uraemia (late)	Sallow complexion, excoriations from scratching (pruritus), uraemic frost (very late/severe — rarely seen in modern practice).

Sign	Basis
*CN III palsy (non-pupil-sparing, "surgical")*	*Posterior communicating artery aneurysm* compressing CN III → ptosis, "down and out" eye, fixed dilated pupil ^[3].
Meningismus (neck stiffness, photophobia)	*SAH from ruptured intracranial aneurysm* ^[3].
Focal neurological deficits	Mass effect from large unruptured aneurysm, or stroke from thromboembolic event.

Feature	ADPKD	ARPKD
Inheritance	Autosomal dominant	Autosomal recessive
Gene	PKD1, PKD2	PKHD1
Protein	Polycystin-1, Polycystin-2	Fibrocystin
Onset	Adulthood (30–50 y)	Perinatal/neonatal/childhood
Cyst origin	All nephron segments	Collecting ducts
Cyst appearance	Spherical, variable size	Fusiform, small, radial pattern
Kidney size	Massively enlarged, bosselated	Enlarged, smoother
Liver	Hepatic cysts (function preserved)	Congenital hepatic fibrosis → *portal hypertension, cholangitis* ^[1]
CNS	Cerebral aneurysms (~8–12%)	Not typically
CVS	MVP, aortic root dilatation	Not typical
Renal stones	Common (~20–30%)	Less common
Prognosis	ESRD in 50s–70s	High perinatal mortality; survivors develop CKD + portal HTN

High Yield Summary

Polycystic Kidney Disease — Key Points for Exams:

ADPKD is the most common inherited kidney disease (1 in 400–1000). Autosomal dominant. PKD1 (85%, chromosome 16, worse) vs PKD2 (15%, chromosome 4, milder).
Pathophysiology: ciliopathy → dysfunctional polycystin-1/2 complex on primary cilium → ↓Ca²⁺ influx → ↑cAMP → fluid secretion (CFTR) and cell proliferation (Ras/MAPK, mTOR) → cyst growth.
Two-hit hypothesis: germline mutation + somatic second hit → explains why only 1–5% of nephrons form cysts.
Clinical presentation: flank pain, haematuria, hypertension (early, RAAS-mediated), UTIs, renal stones, bilateral palpable kidneys. Polyuria/nocturia from concentrating defect.
Extrarenal: hepatic cysts (most common), cerebral aneurysms (8–12%) ^[3], MVP, colonic diverticula.
Hypertension occurs early (60% before GFR decline) due to intrarenal RAAS activation from cyst compression of vasculature.
ARPKD: PKHD1 gene, collecting duct cysts, congenital hepatic fibrosis, presents perinatally.
Tolvaptan (V2 receptor antagonist) works by ↓cAMP in collecting duct cells → slows cyst growth.
Screening: first-degree relatives with renal ultrasound; cerebral aneurysm screening with MRA for high-risk patients (FHx of aneurysm/SAH).
ADPKD is a predisposing factor for cerebral aneurysm and SAH ^[3], and acquired cystic kidney disease (from chronic dialysis) is a risk factor for RCC ^[4]^[5].

Active Recall - Polycystic Kidney Disease (Pre-DDx/Dx/Mx)

^[1] Senior notes: felixlai.md (Polycystic kidney disease section) ^[2] Senior notes: Ryan Ho Urogenital.pdf (Section 5.2 Chronic Kidney Disease, p.99) ^[3] Lecture slides: GC 109. Headache and loss of consciousness Acute stroke, subarachnoid haemorrhage and vascular malformation.pdf (p.14, slides 27–28) ^[4] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (p.7 — RCC risk factors including chronic kidney disease and acquired cystic kidney disease) ^[5] Senior notes: maxim.md (RCC risk factors section — PKD and acquired cystic diseases) ^[6] Senior notes: Ryan Ho Fundamentals.pdf (p.115 — Abdominal examination, D/dx of palpable kidneys)

Differential Diagnosis of Polycystic Kidney Disease

When a patient presents with multiple renal cysts — discovered on imaging or suspected from clinical features (bilateral palpable kidneys, haematuria, hypertension in a young patient, family history) — you need a systematic framework to distinguish ADPKD from the many other conditions that can produce renal cysts. This is not just an academic exercise: the prognosis, surveillance requirements, and management differ dramatically between these conditions.

The differential diagnosis can be framed around two clinical scenarios:

"I see multiple renal cysts on imaging — is this ADPKD or something else?" (the cystic kidney DDx)
"I have a patient with bilateral palpable/enlarged kidneys — what's causing this?" (the bilateral renal mass DDx)

We will address both systematically.

A. Differential Diagnosis of Multiple Renal Cysts

This is the primary DDx when you encounter cystic kidneys. The key distinguishing features are: number of cysts, laterality (bilateral vs unilateral), kidney size, family history, extrarenal features, and the patient's age and CKD status.

Feature	Detail
What it is	Acquired, non-hereditary cysts that develop with ageing. The most common cystic "lesion" of the kidney.
Prevalence	~5% at age 40, rising to ~35% by age 60+. Rare in patients < 30 years old. ^[1]
Key distinguishing features	Simple cysts are uncommon in patients < 30, are rarely multiple and bilateral in younger patients, do not cause kidney enlargement, and have no extrarenal manifestations (no liver cysts, no cerebral aneurysms, no family history). ^[1]
Why it matters	This is the condition most commonly confused with early/mild ADPKD, especially in older patients. In a 60-year-old with a few bilateral cysts and no family history, the distinction can be tricky.
Imaging	Thin-walled, anechoic on USG; homogeneous fluid content < 20 Hounsfield units on CT; no enhancement, no septations, smooth walls. ^[7]
How to tell apart from ADPKD	No family history, kidneys are normal size, no extrarenal cysts, cysts meet Bosniak Class I criteria (simple). If in doubt and there is a positive family history, apply the Ravine/Pei age-specific ultrasound criteria.

The Age Rule

Simple renal cysts are uncommon below age 30. If a patient under 30 has multiple bilateral renal cysts, you should think ADPKD (or another genetic cystic disease) rather than "just simple cysts" — especially if there is a family history or if kidneys are enlarged.

Feature	Detail
What it is	Development of multiple bilateral renal cysts in the setting of chronic kidney disease, particularly in patients on long-term haemodialysis (HD) or peritoneal dialysis (PD). ^[1]
Prevalence	~40% of patients on dialysis for 3 years; ~90% after 5–10 years
Pathophysiology	Chronic uraemia and dialysis → tubular obstruction by oxalate crystals and interstitial fibrosis → cystic dilatation of tubules. The hyperplastic epithelium in these cysts is premalignant.
Key distinguishing features	No family history of PKD; kidneys are small to normal in size (or small and shrunken, reflecting the underlying CKD) with a smooth contour; no extrarenal features of ADPKD (no liver cysts, no cerebral aneurysms). ^[1]
Why it matters	Acquired polycystic kidney disease carries a 30× increased risk of developing renal cell carcinoma (RCC) — these patients require yearly USG surveillance for early detection. ^[4]^[5]^[8]
Associated malignancy risk	Chronic kidney disease and acquired cystic kidney disease are risk factors for RCC ^[4]

Critical Distinction

A common exam pitfall: confusing ARCD with ADPKD. The key differentiators are: (1) ARCD kidneys are small or normal (ADPKD kidneys are massively enlarged); (2) ARCD has no family history; (3) ARCD has no extrarenal cysts; (4) ARCD develops in the context of pre-existing CKD/dialysis (the CKD came first, then the cysts appeared), whereas in ADPKD the cysts cause the CKD. ^[1]

Feature	Detail
What it is	A benign condition with multiple cysts confined to one kidney (or even one part of one kidney). ^[1]
Key distinguishing features	Neither bilateral nor progressive. The contralateral kidney is normal. No family history. No extrarenal features.
Why it matters	It is benign and non-progressive — once identified, it requires only periodic surveillance, not the comprehensive management of ADPKD. Must be distinguished from early/asymmetric ADPKD and from multilocular cystic nephroma (a benign neoplasm).

Feature	Detail
What it is	A congenital disorder characterised by tubular dilatation of the collecting ducts confined to the medullary pyramids, with sparing of the renal cortex. ^[1]
Name breakdown	"Medullary" = medulla of kidney, "sponge" = the sponge-like appearance of the dilated collecting ducts on imaging
Pathophysiology	Dilated collecting ducts → urinary stasis in these ectatic ducts → predisposition to nephrocalcinosis (calcium deposits in the renal medulla) and recurrent nephrolithiasis
Key distinguishing features	Kidney size is normal (not enlarged). Cysts are tiny and confined to the medulla only (cortex is spared). Classic imaging finding: "paintbrush" or "bouquet of flowers" appearance on IVU/CTU due to contrast pooling in dilated collecting ducts. No extrarenal manifestations. Usually benign renal function.
Why it matters	MSK is often discovered incidentally during workup for recurrent kidney stones or nephrocalcinosis. It does NOT cause progressive CKD (unlike ADPKD).

5. Genetic Syndromic Conditions with Renal Cysts

These are the other inherited conditions that can mimic PKD. Each has distinctive extrarenal features that help you differentiate them. ^[1]

Feature	Detail
Inheritance	Autosomal dominant (TSC1 on chromosome 9, TSC2 on chromosome 16)
Renal manifestations	Angiomyolipomas (AMLs) (most common, ~80%), renal cysts (~50%), and rarely RCC (< 5%) ^[8]
Key distinguishing features	The classic triad: seizures, intellectual disability, facial angiofibromas (adenoma sebaceum). Also: ash-leaf macules, shagreen patches, subungual fibromas, cortical tubers, subependymal giant cell astrocytomas (SEGA), cardiac rhabdomyomas, retinal hamartomas, lymphangioleiomyomatosis (LAM) in women.
Why the confusion	TSC2 is on chromosome 16, adjacent to PKD1. There is a recognized TSC2/PKD1 contiguous gene deletion syndrome where patients have both TSC and severe, very early-onset ADPKD. This is rare but extremely severe.
How to distinguish	Look for the dermatological and neurological stigmata of TSC. AMLs (which contain fat, visible on CT) are the signature renal finding, not pure cysts.

Feature	Detail
Inheritance	Autosomal dominant (VHL gene on chromosome 3p25)
Renal manifestations	Renal cysts (75%), clear cell RCC (40%) — bilateral and multifocal ^[8]
Key distinguishing features	Cerebellar haemangioblastomas, retinal angiomas (retinal capillary haemangioblastomas), phaeochromocytomas (14%), pancreatic cysts, endolymphatic sac tumours, epididymal cystadenomas ^[8]
RCC association	Genetic predisposition: Family history and inherited syndromes such as von Hippel-Lindau... ^[4]
How to distinguish	The extrarenal features are completely different from ADPKD. VHL patients get CNS haemangioblastomas and retinal angiomas — ADPKD patients get cerebral aneurysms and liver cysts. Also, VHL-associated renal lesions include both cysts AND solid tumours (RCC), whereas ADPKD cysts are benign.

Feature	Detail
Inheritance	Autosomal dominant (HNF1B gene on chromosome 17)
Renal manifestations	Renal cysts (often bilateral), renal hypoplasia, single kidney, other renal developmental anomalies
Key distinguishing features	MODY5 (maturity-onset diabetes of the young type 5), pancreatic hypoplasia, genital tract malformations, hyperuricaemia, hypomagnesaemia, abnormal LFTs
How to distinguish	Young-onset diabetes + renal cysts + genital anomalies → think HNF1B. Kidneys are NOT massively enlarged.

Feature	Detail
Inheritance	X-linked dominant (lethal in males)
Renal manifestations	Bilateral renal cysts resembling ADPKD
Key distinguishing features	Oral findings (cleft lip/palate, lobulated tongue, oral frenulae), facial findings (facial asymmetry, milia), digital findings (brachydactyly, syndactyly)

While this is a form of PKD itself (not strictly a "differential" of PKD broadly), it is a critical differential for ADPKD specifically:

Feature	ADPKD	ARPKD
Age at presentation	Adults (30–50y)	Perinatal/neonatal/childhood
Inheritance	AD	AR
Kidney appearance on USG	Large, macrocysts, variable size	Large, hyperechoic, loss of corticomedullary differentiation; tiny cysts in radial pattern
Liver	Hepatic cysts	Congenital hepatic fibrosis → portal hypertension, cholangitis, biliary dysgenesis ^[1]
Family history	Parent affected (50% chance)	Parents are carriers (both unaffected); sibling recurrence risk 25%

Feature	Detail
What they are	A group of tubulointerstitial ciliopathies causing corticomedullary cysts (small, at the corticomedullary junction) with progressive CKD
Inheritance	NPHP: autosomal recessive (children/adolescents); MCKD: autosomal dominant (adults)
Key distinguishing features	Kidneys are normal or small (NOT enlarged — this is the key). Cysts are small and concentrated at the corticomedullary junction. Prominent tubulointerstitial fibrosis with salt-wasting and concentrating defect (polyuria, polydipsia). NPHP is a leading genetic cause of ESRD in children.
How to distinguish	The kidneys are NOT enlarged (in fact, often shrunken). No extrarenal cysts (liver, pancreas). NPHP may be associated with retinitis pigmentosa (Senior-Løken syndrome), cerebellar vermis hypoplasia (Joubert syndrome), or hepatic fibrosis.

When you find bilateral renal masses on examination, the DDx extends beyond cystic diseases to include any cause of bilateral renal enlargement: ^[6]

Category	Condition	Key Distinguishing Feature
Congenital/Genetic	ADPKD	Bilateral bosselated kidneys, FHx, hepatomegaly from polycystic liver, hypertension
Endocrine	Diabetic nephropathy (early)	Long-standing DM, kidneys enlarged from hyperfiltration in early DMN (NOT shrunken initially); nephromegaly is common in early DMN ^[9]
Endocrine	Acromegaly	Visceromegaly affecting all organs; coarsened facial features, large hands/feet
Infiltrative	Amyloidosis	Nephrotic syndrome, macroglossia, carpal tunnel, cardiac involvement (restrictive cardiomyopathy)
Infiltrative	Lymphoma	Constitutional symptoms (B symptoms), lymphadenopathy, splenomegaly
Vascular	Bilateral renal vein thrombosis	Acute flank pain, haematuria; seen in nephrotic syndrome (hypercoagulable state)
Obstructive	Bilateral hydronephrosis	Obstruction must be at bladder outlet or bilateral ureteric level; palpable bladder, BPH, pelvic malignancy
Infection	Bilateral pyelonephritis/abscess	Fever, rigors, bilateral loin tenderness, pyuria
Bilateral causes of unilateral masses	Bilateral RCC (extremely rare)	Constitutional symptoms, haematuria, paraneoplastic features

^[6]

Exam Approach to Bilateral Palpable Kidneys

When asked for a DDx of bilateral palpable kidneys, use this structured approach: Congenital (ADPKD — most common), Endocrine (diabetic nephropathy, acromegaly), Infiltrative (amyloid, lymphoma), Obstructive (bilateral hydronephrosis), Others (bilateral RCC, bilateral renal vein thrombosis). The unilateral causes occurring bilaterally should also be mentioned. ^[6]

C. Differential Diagnosis by Presenting Feature

ADPKD can present in several ways, and each presentation has its own DDx:

Haematuria is a common presentation of ADPKD (cyst haemorrhage into collecting system). The broader DDx of haematuria relevant here ^[7]^[10]:

Source	Condition	Distinguishing Feature
Renal — cystic	ADPKD	Bilateral flank masses, FHx, insidious onset HTN ^[10]
Renal — glomerular	IgA nephropathy	Synpharyngitic haematuria (concurrent with URTI), dysmorphic RBCs/RBC casts on urine microscopy
Renal — glomerular	Alport syndrome	X-linked, sensorineural hearing loss, anterior lenticonus
Renal — neoplastic	RCC	Painless haematuria + flank pain + palpable mass (classic triad, uncommon); constitutional symptoms, paraneoplastic syndrome ^[10]
Ureteric	Urolithiasis	Unilateral flank colic radiating to groin, isomorphic RBCs
Bladder	CA bladder	Painless haematuria in older smoker, irritative LUTS
Prostate	CA prostate/BPH	Obstructive LUTS, abnormal DRE
Infection	UTI/Pyelonephritis	Fever, dysuria, frequency, pyuria, positive culture

^[10]

ADPKD is an important cause of secondary hypertension via renal parenchymal disease. When a young patient (< 30–40) presents with hypertension, the DDx includes ^[3]:

Category	Condition	Key Feature
Renal parenchymal disease	ADPKD	Haematuria, proteinuria, recurrent UTI, frequency, nocturia, FHx of polycystic kidney disease ^[3]
Renal vascular	Renal artery stenosis	Abrupt onset, renal bruit, flash pulmonary oedema
Endocrine	Primary aldosteronism	Hypokalaemia, metabolic alkalosis, muscle weakness
Endocrine	Phaeochromocytoma	Paroxysmal HTN, headache, sweating, palpitations
Endocrine	Cushing's syndrome	Central obesity, striae, proximal myopathy
Cardiovascular	Coarctation of aorta	Radiofemoral delay, UL > LL BP
Other	OSA	Obesity, snoring, daytime sleepiness

High Yield: When screening for secondary hypertension, renal USG is the initial investigation for renal parenchymal disease, including ADPKD ^[3]. The clinical clues for ADPKD as a cause of secondary HTN are: family history, bilateral flank masses, haematuria, and features of extrarenal disease.

Condition	Kidney Size	Laterality	Cyst Size	FHx	Extrarenal Features	Age
ADPKD	Massively enlarged	Bilateral	Variable, large	+ (AD)	Liver cysts, cerebral aneurysm, MVP	Adult
ARPKD	Enlarged	Bilateral	Small, fusiform	+ (AR)	Congenital hepatic fibrosis	Perinatal/child
Simple cysts	Normal	Uni- or bilateral	Variable	–	None	> 40–50
ARCD	Small/normal	Bilateral	Small	–	None; but ↑RCC risk	On dialysis
MSK	Normal	Bilateral	Tiny (medullary)	–	None; nephrocalcinosis	Any
TSC	Normal/slightly enlarged	Bilateral	Variable; + AMLs	+ (AD)	Skin lesions, seizures, CNS tubers	Any
VHL	Normal	Bilateral	Variable; + RCC	+ (AD)	Haemangioblastomas, phaeochromocytoma	Any
NPHP/MCKD	Normal/small	Bilateral	Small (CMJ)	+	Retinitis pigmentosa, Joubert	Child/adult
Localized cystic ds	Normal	Unilateral	Variable	–	None	Any

High Yield Summary — Differential Diagnosis of PKD

The most common DDx for ADPKD is multiple benign simple cysts — distinguished by age (simple cysts rare < 30y), kidney size (normal in simple cysts), and absence of FHx/extrarenal features.
Acquired cystic kidney disease occurs in chronic dialysis patients — kidneys are small/normal (not enlarged), no FHx, no extrarenal cysts, but carries 30× RCC risk requiring yearly USG surveillance.
Key genetic DDx: TSC (AMLs, skin lesions, seizures), VHL (haemangioblastomas, RCC, phaeochromocytoma), HNF1B (MODY5 + cysts).
Medullary sponge kidney: medullary-only cysts, normal-sized kidneys, presents with stones/nephrocalcinosis.
ARPKD: collecting duct cysts + congenital hepatic fibrosis, presents perinatally.
For bilateral palpable kidneys: most common cause is ADPKD; also consider diabetic nephropathy (early), amyloidosis, lymphoma, bilateral hydronephrosis.
ADPKD is an important cause of secondary hypertension in young patients — screen with renal USG.

Active Recall - Differential Diagnosis of PKD

References

^[1] Senior notes: felixlai.md (Polycystic kidney disease section — differential diagnosis) ^[3] Senior notes: Ryan Ho Cardiology.pdf (p.178 — Secondary hypertension screening table) ^[4] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (p.7 — RCC risk factors) ^[5] Senior notes: maxim.md (RCC risk factors section) ^[6] Senior notes: Ryan Ho Fundamentals.pdf (p.115 — D/dx of palpable kidneys) ^[7] Senior notes: Ryan Ho Urogenital.pdf (p.151 — Simple renal cysts) ^[8] Senior notes: Ryan Ho Urogenital.pdf (p.145 — RCC risk factors including VHL, TSC, acquired cystic disease) ^[9] Senior notes: Ryan Ho Urogenital.pdf (p.85 — Diabetic nephropathy, nephromegaly) ^[10] Senior notes: Ryan Ho Urogenital.pdf (p.130 — Approach to haematuria table)

Diagnostic Criteria, Algorithm, and Investigation Modalities for ADPKD

The diagnosis of ADPKD rests on a deceptively simple foundation: demonstrating multiple bilateral renal cysts in the appropriate clinical context (family history, age, extrarenal features). The challenge is that simple renal cysts are extremely common in the general population and increase with age, so you need age-specific criteria to distinguish pathological cyst numbers from the background noise of acquired simple cysts.

There are three tiers of diagnosis:

Imaging-based criteria (ultrasound, CT, or MRI) — the mainstay for most patients
Genetic testing — reserved for equivocal imaging, very young patients, potential living kidney donors, or when a definitive diagnosis is critical
Clinical diagnosis — in patients with classic presentation (bilateral massive kidneys, hepatic cysts, positive family history), imaging alone is sufficient; no biopsy is needed

Key Principle

ADPKD is diagnosed clinically and radiologically. Renal biopsy is NOT required and is in fact contraindicated in established PKD (haemorrhage risk from cysts, and the histology is non-specific). The diagnosis is made by counting cysts on imaging in the context of age and family history.

A. Diagnostic Criteria

A1. Patients WITH a Positive Family History of ADPKD

These are the Ravine criteria (originally 1994) updated by Pei et al. (2009) — the most widely used ultrasound-based criteria. The logic: since cysts accumulate with age in ADPKD, the threshold number of cysts required for diagnosis varies by age group. Younger patients need fewer cysts because having ANY bilateral cysts at a young age is abnormal. ^[1]

Age Group	Criteria for Diagnosis	Criteria to EXCLUDE ADPKD
15–29 years	≥ 3 cysts (unilateral or bilateral)	≤ 1 cyst (excludes PKD1 with near-100% NPV)
30–39 years	≥ 3 cysts (unilateral or bilateral)	≤ 1 cyst
40–59 years	≥ 2 cysts in each kidney	≤ 1 cyst in each kidney
≥ 60 years	≥ 4 cysts in each kidney	≤ 2 cysts in each kidney

^[1]

USG criteria are less sensitive for patients with PKD2 mutation because of the late onset of cystogenesis — cysts develop later and more slowly in PKD2. ^[1]

Age Group	Criteria for Diagnosis
15–39 years	≥ 3 cysts (unilateral or bilateral)
40–59 years	≥ 2 cysts in each kidney
≥ 60 years	≥ 4 cysts in each kidney

^[1]

Why the Numbers Change with Age

In the general population, simple renal cysts are uncommon before age 30 but increasingly common after age 50. Therefore, finding 3 cysts in a 20-year-old is highly significant, but finding 3 cysts in a 70-year-old could just be age-related. This is why the diagnostic threshold increases with age — you need more cysts at older ages to confidently say they are not just incidental simple cysts.

Exam Pitfall: Exclusion Criteria

The Pei criteria also provide exclusion criteria — the ability to tell an at-risk individual that they do NOT have ADPKD. For a patient aged 15–29 with a PKD1 parent, having ≤ 1 cyst essentially excludes the disease. However, for patients under 15, ultrasound cannot reliably exclude ADPKD because cysts may not have developed yet. Direct genetic testing for the known mutation in patients at risk for PKD2 may be more cost-effective than USG in younger individuals. ^[1]

This is trickier because ~10% of ADPKD cases are de novo mutations (no affected parent), and sometimes family history is incomplete. ^[1]

There is NO definitive number of cysts or cyst location that provides a definite diagnosis in this scenario. ^[1]

Diagnosis should be strongly suspected if:

Presence of multiple and bilateral cysts, arbitrarily defined as ≥ 10 cysts in each kidney ^[1]
Presence of renal enlargement (total kidney length > 16.5 cm) or liver cysts ^[1]
Absence of findings suggestive of a different renal cystic disease (no features of TSC, VHL, ACKD, etc.) ^[1]

In these patients, genetic testing becomes more important to confirm the diagnosis.

MRI and CT are more sensitive than ultrasound and can detect smaller cysts (< 1 cm). The Pei criteria were designed for ultrasound. When MRI is used:

CT/T2-weighted MRI with or without contrast is more sensitive than USG in detecting cysts of smaller size ^[1]
MRI is the preferred modality for total kidney volume (TKV) measurement (used for Mayo classification and tolvaptan eligibility)
For MRI, a threshold of ≥ 10 total cysts in a patient aged 15–30 with a positive family history has ~100% sensitivity and specificity for ADPKD

Genetic testing is indicated in patients with equivocal imaging or when a definitive diagnosis is required. ^[1]

Specific indications for genetic testing:

Equivocal ultrasound findings (borderline cyst counts)
Young patients (< 15 years) where USG is unreliable
No family history (de novo suspected)
Potential living related kidney donor — MUST definitively exclude ADPKD before donation
Distinguishing PKD1 from PKD2 (important for prognosis and tolvaptan eligibility)
Reproductive counselling / preimplantation genetic diagnosis
Atypical presentations (early-onset severe disease → consider contiguous gene deletion with TSC2)

Methods:

Next-generation sequencing (NGS) panels covering PKD1, PKD2, and other cystic kidney disease genes (PKHD1, HNF1B, TSC1/2, etc.)
Multiplex ligation-dependent probe amplification (MLPA) — detects large deletions/duplications not picked up by sequencing
Note: PKD1 gene sequencing is technically challenging because ~75% of the gene has 6 pseudogenes on chromosome 16 with > 97% sequence homology → requires specialised long-range PCR techniques

C. Investigation Modalities

The clinical assessment is the starting point — not an afterthought. ^[1]

History Taking Checklist: ^[1]

Domain	What to Ask	Why
HPI	Polyuria, nocturia, frequency, thirst	Earliest manifestation — concentrating defect from medullary disruption ^[1]
	Haematuria (gross or microscopic)	Cyst haemorrhage, stones
	Flank or back pain	Cyst enlargement, haemorrhage, infection, stones
	Headache	Suggests intracranial aneurysm (ICA) ^[1]
Medical History	CVS: Hypertension, intracranial aneurysm, stroke, valvular heart disease	Extrarenal associations ^[1]
	GI: Liver cyst, pancreatic cyst, colonic diverticulum, abdominal wall hernia	Extrarenal cysts and connective tissue manifestations ^[1]
	UG: Renal stones	20–30% prevalence in ADPKD ^[1]
Family history	ADPKD, ESRD, dialysis, transplant, cerebral aneurysm, SAH, early stroke	Establishes inheritance pattern and risk

Physical Examination: ^[1]^[6]

Finding	Significance
BP measurement	Crucial — present in majority with normal renal function by age 40; occurs early prior to loss of kidney function and is associated with progressive renal disease ^[1]
Bilateral ballotable kidneys	Hallmark sign — enlarged, bosselated, bimanually palpable ^[1]^[6]
Hepatomegaly	Polycystic liver — firm, nodular ^[1]^[6]
Abdominal wall hernia	Connective tissue weakness + chronic increased intra-abdominal pressure ^[1]
Cardiac auscultation	Mid-systolic click (mitral valve prolapse)

Investigation	Key Findings in ADPKD	Interpretation / Why
CBC with differentials	Anaemia or erythrocytosis	Anaemia from chronic haematuria or CKD; erythrocytosis from compensatory increase in EPO production by cyst lining cells (ADPKD patients maintain relatively higher Hb than other CKD patients at same GFR) ^[1]
RFT (urea, creatinine, eGFR, electrolytes)	Elevated creatinine, ↓eGFR (late); hyperkalaemia (late CKD)	Renal function usually remains normal until the 40s — monitors for development of ESRD ^[1]. Normal RFT does NOT exclude ADPKD.
Urinalysis	Haematuria (microscopic or gross); proteinuria	Proteinuria is NOT a major feature of ADPKD and usually reflects a superimposed glomerular disease if present ^[1]. Modest proteinuria (< 1 g/day) is common; heavy proteinuria should prompt consideration of an additional glomerulopathy.
Urine microscopy	Isomorphic RBCs (non-glomerular origin from cyst rupture)	Helps distinguish from glomerular haematuria (dysmorphic RBCs, RBC casts) ^[11]^[13]
Urine culture	Rule out UTI / cyst infection	ADPKD patients are prone to UTI from urinary stasis
Serum uric acid	May be elevated	Contributes to uric acid stone formation (low urinary pH + stasis)
Lipid profile	Dyslipidaemia	Common in CKD; requires treatment with statins
Calcium, phosphate, PTH	HypoCa, hyperPO4, ↑PTH (late CKD)	CKD-MBD (mineral bone disease) — loss of 1α-hydroxylase activity as nephrons are destroyed

C3. Radiological Investigations

Aspect	Detail
Role	First-line screening and diagnostic tool, indicated in screening of asymptomatic individuals with positive family history ^[1]^[3]^[12]
Findings in ADPKD	Enlarged kidneys with extensive cysts scattered throughout both kidneys ^[1]; loss of corticomedullary differentiation; cysts are anechoic, round, with posterior acoustic enhancement; variable size (mm to > 10 cm); kidneys > 15 cm
Findings in ARPKD	Bilateral enlarged hyperechoic kidneys (innumerable tiny cysts below USG resolution create increased echogenicity); loss of corticomedullary differentiation; "pepper and salt" appearance
Hepatic assessment	Polycystic liver — multiple hepatic cysts of varying size
Advantages	No radiation, no contrast, cheap, widely available, bedside, repeatable; excellent for cyst detection ≥ 1 cm
Limitations	Less sensitive for PKD2 due to fewer/smaller cysts at younger ages ^[1]; operator-dependent; limited for small cysts (< 0.5–1 cm); cannot accurately measure TKV; limited for detecting complications (cyst haemorrhage vs infection)
When to use it	Initial screening, diagnosis in patients with positive FHx, follow-up, and when screening for renal parenchymal disease as cause of secondary hypertension ^[3]

High Yield: Renal USG is the screening investigation for renal parenchymal disease (including polycystic kidney) in the workup of secondary hypertension ^[3]. Large kidneys on USG can occur in polycystic kidneys, infiltrative disease, or obstructive uropathy ^[12].

Aspect	Detail
Role	More sensitive than USG in detecting cysts of smaller size ^[1]; indicated when USG is equivocal, or for evaluating complications
Findings in ADPKD	Bilateral massively enlarged kidneys with innumerable cysts of varying size replacing normal parenchyma; calcification within cyst walls (chronic haemorrhage); renal stones; complicated cysts (haemorrhagic cysts appear hyperdense > 20 HU)
CT for complications	Cyst haemorrhage (hyperdense cyst > 50 HU on non-contrast CT); cyst infection (rim enhancement, wall thickening, gas within cyst — rare); renal stones (NCCT is gold standard for stone detection)
CT with contrast of brain	Initial diagnostic test for intracranial aneurysm ^[1] — CTA of cerebral vessels for screening/diagnosis of aneurysm in ADPKD patients with FHx of aneurysm or SAH
Limitations	Not usually preferred due to potential contrast nephropathy and allergic reactions in patients with CKD ^[1]; radiation exposure; not ideal for serial TKV monitoring
When to use	Equivocal USG; evaluation of acute complications (haemorrhage, infection, stones); suspected RCC within a cyst; pre-surgical planning

Contrast Caution in CKD

ADPKD patients often have CKD. Iodinated contrast agents carry a risk of contrast-induced nephropathy (CIN), especially at eGFR < 30. Always weigh the benefits of contrast CT against this risk. For serial monitoring, MRI (without gadolinium if possible) is preferred over repeated CT. If eGFR < 30, avoid gadolinium-based contrast due to risk of nephrogenic systemic fibrosis (NSF).

Aspect	Detail
Role	Gold standard for total kidney volume (TKV) measurement; most sensitive for cyst detection; distinguishes cyst content (haemorrhagic vs serous)
Findings in ADPKD	T2W: cysts appear bright (high signal) due to fluid content; hemorrhagic cysts appear bright on T1W (due to methemoglobin); accurate delineation of cyst number, size, and total kidney volume
TKV measurement	Measured using stereological or ellipsoid methods on MRI. Height-adjusted TKV (htTKV) is used for Mayo Imaging Classification (Classes 1A–1E), which determines eligibility for tolvaptan.
MRA brain	Magnetic resonance angiography — non-invasive screening for intracranial aneurysms in high-risk ADPKD patients
Advantages	No radiation; no iodinated contrast needed (T2W sequences are diagnostic without contrast); superior soft tissue contrast; accurate volumetry
Limitations	Expensive; time-consuming; claustrophobia; not available at bedside; gadolinium contraindicated if severe CKD (NSF risk)
When to use	TKV measurement for risk stratification and tolvaptan eligibility; equivocal USG in young patients; distinguishing haemorrhagic from infected cysts; serial monitoring

Modality	Role in ADPKD
KUB plain radiograph	Initial screening for radio-opaque renal stones; may show bilateral enlarged kidney shadows ^[13]
IVU	Largely replaced by CTU; historically showed "Swiss cheese" or "moth-eaten" calyceal pattern from cyst compression. No longer first-line. ^[11]
Echocardiography	Screening for mitral valve prolapse and left ventricular hypertrophy from chronic hypertension

Aspect	Detail
Indication	Indicated in patients with equivocal imaging or when a definite diagnosis is required ^[1]
Methods	Next-generation sequencing (NGS) covering PKD1, PKD2 ± other genes (PKHD1, HNF1B, TSC1/2, etc.); MLPA for large deletions; Long-range PCR required for PKD1 due to pseudogenes
Detection rate	~85–90% in clinically diagnosed ADPKD (pathogenic variant identified)
Specific indications	(1) Equivocal imaging; (2) Young patients < 15y; (3) No family history; (4) Potential living related kidney donor; (5) Distinguishing PKD1 vs PKD2 for prognosis; (6) Reproductive counselling / PGD; (7) Atypical presentations
Limitation	~10% of clinically diagnosed ADPKD patients have no identifiable mutation ("genetically unresolved ADPKD") — likely due to mosaicism, deep intronic variants, or novel genes

Screening Test	Indication	What It Detects
MRA brain / CTA brain	Family history of intracranial aneurysm or SAH; or symptoms (thunderclap headache, CN III palsy) ^[1]	Intracranial aneurysm (~8–12% prevalence in ADPKD)
Echocardiography	Baseline screening; clinical suspicion of murmur	Mitral valve prolapse (~25%), aortic root dilatation, LVH
Liver USG/MRI	Part of initial imaging; symptoms of hepatomegaly	Polycystic liver disease (most common extrarenal manifestation)
Ambulatory BP monitoring	Early disease, all patients	Hypertension (often presents before GFR decline)

Intracranial Aneurysm (ICA) Screening Protocol:

Who to screen: ADPKD patients with a family history of intracranial aneurysm, SAH, or unexplained sudden death ^[1]
How: MRA (preferred — non-invasive, no radiation, no iodinated contrast) or CTA
When: At diagnosis, then repeat every 5 years if initial screen is negative; every 1–2 years if aneurysm < 7 mm is found and managed conservatively
Routine screening in ADPKD patients WITHOUT a family history of aneurysm is controversial — not universally recommended due to low absolute risk, though some centres offer it

When NOT to Screen for ICA

Routine MRA screening for all ADPKD patients without a family history of aneurysm/SAH is NOT currently standard practice. The overall rupture rate of small incidental aneurysms is very low, and the anxiety and potential harm from incidental findings (and subsequent interventions) may outweigh benefits in low-risk patients. Screen ONLY those with positive FHx, symptoms, or high-risk occupations (e.g., airline pilots).

Once ADPKD is diagnosed, the next step is determining how fast the disease will progress — this guides tolvaptan eligibility:

Tool	What It Measures	Clinical Application
Mayo Imaging Classification	htTKV on MRI → Classes 1A (low risk) to 1E (very high risk)	Identifies patients with rapid progression eligible for tolvaptan (typically 1C–1E)
PROPKD Score	Genotype (PKD1 truncating > PKD1 non-truncating > PKD2) + clinical variables (hypertension < 35y, urological event < 35y, male sex)	Score 0–9: Low (0–3), Intermediate (4–6), High (7–9) risk of ESRD before 60
eGFR trajectory	Serial eGFR measurements over time	Decline > 2.5 mL/min/year suggests rapid progression
Baseline eGFR + TKV	Combined assessment	KDIGO 2015 recommends using both for prognosis

Category	Investigations
Confirm diagnosis	Renal USG (apply Pei criteria) ± MRI ± genetic testing
Baseline renal function	RFT (Cr, eGFR, electrolytes), urinalysis (haematuria, proteinuria), urine culture
Haematological	CBC (anaemia vs erythrocytosis)
Metabolic / CKD-MBD	Calcium, phosphate, PTH, vitamin D, uric acid (if stones), lipid profile
Cardiovascular	BP (ambulatory if needed), ECG, echocardiography
Prognostic	MRI for TKV → Mayo classification; genetic testing if needed for PROPKD score
Extrarenal screening	Liver USG/MRI; MRA brain (if FHx of aneurysm/SAH); echocardiography (MVP)
Complication assessment	NCCT if stones suspected; CT/MRI if cyst haemorrhage/infection suspected

High Yield Summary — Diagnosis of ADPKD

Diagnosis is clinical + imaging: Renal USG is first-line. Apply age-specific Pei-Ravine criteria in patients with positive FHx. In patients without FHx, ≥ 10 cysts per kidney + enlarged kidneys + no alternative diagnosis strongly suggests ADPKD.
USG is less sensitive for PKD2 due to late-onset cystogenesis → consider MRI or direct genetic testing.
Genetic testing is indicated for equivocal imaging, very young patients, potential kidney donors, and when definitive diagnosis is required. ^[1]
Proteinuria is NOT a major feature of ADPKD — if heavy proteinuria is present, suspect superimposed glomerulopathy. ^[1]
Renal function usually remains normal until the 40s — normal RFT does NOT exclude ADPKD. ^[1]
MRI is the gold standard for TKV measurement → Mayo classification (1A–1E) → determines tolvaptan eligibility.
MRA/CTA brain is the initial test for intracranial aneurysm screening in high-risk patients (FHx of aneurysm/SAH). ^[1]
Risk stratification: Mayo classification (htTKV), PROPKD score (genotype + clinical), eGFR trajectory.
CBC may show anaemia (CKD or haematuria) or erythrocytosis (compensatory EPO production). ^[1]

Active Recall - Diagnosis of ADPKD

References

^[1] Senior notes: felixlai.md (Polycystic kidney disease — Diagnosis section, Clinical manifestation section) ^[3] Senior notes: Ryan Ho Cardiology.pdf (p.177–178 — Secondary hypertension workup, screening for renal parenchymal disease) ^[6] Senior notes: Ryan Ho Fundamentals.pdf (p.115 — Abdominal examination, D/dx of palpable kidneys) ^[11] Senior notes: Ryan Ho Diagnostic Radiology.pdf (p.17 — Intravenous Urogram) ^[12] Senior notes: Ryan Ho Urogenital.pdf (p.102 — Initial evaluation for renal impairment, USG kidney findings) ^[13] Senior notes: Ryan Ho Urogenital.pdf (p.133–134 — Investigations for haematuria, KUB, cystoscopy, CT urogram)

Management of ADPKD

Let me frame this clearly. ADPKD management has four pillars:

Slow disease progression (the holy grail — delay ESRD by years)
Manage complications (pain, infection, stones, haematuria, hypertension)
Screen for and manage extrarenal manifestations (cerebral aneurysms, liver cysts, cardiac)
Renal replacement therapy when ESRD inevitably arrives

Until 2015, we had NO disease-modifying therapy — only supportive measures. The approval of tolvaptan changed the landscape. But the reality is that most of the management is still about good CKD care, aggressive BP control, and dealing with complications as they arise.

B. Detailed Management

These are the foundation of management for ALL ADPKD patients, regardless of disease stage.

Measure	Detail	Rationale (First Principles)
Dietary sodium restriction < 2 g/day	Equivalent to < 5 g NaCl/day	Reduces extracellular volume expansion → ↓BP; high salt intake independently accelerates cyst growth via osmotic mechanisms and volume-mediated RAAS stimulation ^[1]
Increased fluid intake (2.5–3 L/day)	Water is the preferred fluid; spread throughout the day including before bed	Suppresses vasopressin level, which is postulated to be a therapeutic mechanism to inhibit cystic growth in ADPKD ^[1]. The logic: water intake → ↓serum osmolality → ↓ADH release → ↓V2 receptor activation → ↓cAMP in collecting duct cells → ↓cyst growth. This is the same pathway that tolvaptan targets pharmacologically.
Avoid caffeine	Limit coffee, tea, energy drinks	Caffeine inhibits phosphodiesterase → ↓cAMP breakdown → ↑cAMP accumulation → theoretically accelerates cyst growth
Regular exercise	30 min/day, most days of the week; avoid contact sports if kidneys very large	Cardiovascular benefit, weight control, ↓BP. Avoid contact sports/activities with high risk of abdominal trauma (risk of cyst rupture/haemorrhage in very enlarged kidneys).
Moderate protein intake	0.8–1.0 g/kg/day if CKD stage 3+; avoid high protein > 1.3 g/kg/day	Reduces hyperfiltration in remaining nephrons; excessive protein → ↑urea generation → ↑uraemic symptoms ^[14]
Weight control	Maintain BMI 18.5–25	Obesity is an independent risk factor for CKD progression and CVD
Smoking cessation	Absolute	Smoking accelerates CKD progression and is a major CVD risk factor

B2. Blood Pressure Control

Hypertension is the earliest treatable risk factor in ADPKD and the single most important modifiable factor for slowing CKD progression and reducing cardiovascular morbidity.

The HALT-PKD trial (2014) established the evidence base:

Patient Profile	BP Target	Evidence
Age 18–50 with eGFR > 60	< 95/60 to 110/75 (i.e. < 110/75) for HALT-PKD; practically ≤ 130/80 per KDIGO	HALT-PKD Study A showed that intensive BP control (95–110/60–75) slowed TKV growth and reduced LVH, urinary albumin excretion, and LV mass index
Older patients or eGFR < 60	140/90 mmHg	Do NOT maintain SBP to 110 mmHg in patients with moderate or advanced disease since it may increase the risk of renal disease progression by reducing renal blood flow ^[1]

Why Intensive BP Harms in Advanced CKD

In advanced CKD (eGFR < 60), the remaining nephrons are already maximally vasodilated to maintain filtration. If you drop systemic BP too low, you reduce perfusion to these nephrons below the autoregulatory threshold → ischaemia → paradoxically accelerate nephron loss. This is why we are MORE aggressive with BP lowering in early disease (where the kidneys can still autoregulate) and MORE cautious in advanced disease. ^[1]

Drug	Role	Rationale
ACEI (first-line)	First-line antihypertensive unless contraindicated	Increased RAAS activity and extracellular volume expansion is involved in the pathogenesis of hypertension in patients with ADPKD ^[1]. ACEI blocks Ang I → Ang II conversion → ↓vasoconstriction, ↓aldosterone, ↓sodium retention. Also has antiproteinuric and antifibrotic effects.
ARB	Should be considered in patients intolerant of ACEI due to dry cough or angioedema	ARB blocks the Ang II type 1 receptor directly. Same downstream effects as ACEI but without the bradykinin accumulation that causes cough (ACEI inhibits kininase II, which normally degrades bradykinin → ↑bradykinin → cough). ^[1]
Dual ACEI + ARB	NOT recommended routinely	HALT-PKD Study A tested ACEI + ARB combination. No additional benefit in TKV or eGFR preservation over ACEI alone, but ↑risk of hyperkalaemia and AKI.
CCB, diuretics, beta-blockers	Second-line add-on agents	Used when BP not controlled with ACEI/ARB alone. Standard hypertension combination approach: A + C, then A + C + D ^[3]

High Yield: Control of BP can prevent progression of renal disease and decreases the risk of cardiovascular morbidity ^[1]. ACEI/ARB are preferred in ADPKD even though they do NOT have the same strong anti-proteinuric rationale as in diabetic CKD (because proteinuria is NOT a major feature of ADPKD ^[1]). The benefit is primarily through RAAS blockade and BP lowering. ^[14]

B3. Disease-Modifying Therapy: Tolvaptan

This is the landmark advance in ADPKD management. Tolvaptan ("tolva" = tolvaptan, "ptan" = vasopressin receptor antagonist, member of the "vaptan" class) is a selective vasopressin V2-receptor antagonist.

ADH (vasopressin) binds V2 receptors on the basolateral membrane of collecting duct principal cells
V2 receptor activation → Gs protein → adenylyl cyclase activation → ↑cAMP
In ADPKD, the polycystin defect means cAMP is already unopposed (because the Ca²⁺-mediated brake on cAMP is lost)
cAMP drives: (a) CFTR Cl⁻ secretion → fluid into cyst; (b) cell proliferation → cyst wall growth
Tolvaptan blocks V2 receptors → ↓adenylyl cyclase activation → ↓cAMP → ↓fluid secretion + ↓cell proliferation → slowed cyst growth
Side effect: blocking V2 receptors also blocks ADH-mediated aquaporin-2 insertion → aquaresis (free water excretion) → polyuria + polydipsia + thirst (essentially iatrogenic nephrogenic DI)

Trial	Design	Key Finding
TEMPO 3:4 (2012)	RCT, n=1445, 3 years	Tolvaptan slowed TKV growth by 49% (2.8% vs 5.5%/year) and reduced rate of GFR decline
REPRISE (2017)	RCT, n=1370, 1 year	Tolvaptan slowed eGFR decline by 1.27 mL/min/year in later-stage CKD (eGFR 25–65). Extended indication to CKD stages 2–4.

Tolvaptan is indicated for adults with ADPKD who are at risk of rapid disease progression:

Criterion	Detail
Age	18–55 years (limited data in older patients)
eGFR	> 25 mL/min/1.73m² (benefit diminishes below this)
Evidence of rapid progression	Mayo Class 1C–1E (htTKV growth > 3%/year); OR confirmed eGFR decline > 2.5 mL/min/year over 5 years; OR PROPKD score ≥ 7
CKD stage	Typically CKD stages 1–4 (eGFR 25–90+)

Contraindication	Reason
Liver disease (hepatic impairment)	Tolvaptan is hepatotoxic — can cause idiosyncratic drug-induced liver injury (DILI). Fatal hepatotoxicity has been reported. Requires monthly LFT monitoring for first 18 months, then every 3 months.
Volume depletion / inability to drink water	Tolvaptan causes massive aquaresis (up to 6–8 L/day of dilute urine). If the patient cannot freely access water, they will become severely dehydrated and hypernatraemic.
Pregnancy and breastfeeding	Teratogenic risk; women of childbearing age must use effective contraception.
Hypovolaemia / hypernatraemia	Will be worsened by aquaresis
Anuria	No benefit if kidneys are non-functional
Unable to perceive thirst	Risk of severe dehydration

Parameter	Frequency	Reason
LFTs (ALT, AST, bilirubin)	Monthly for first 18 months, then every 3 months	DILI risk — stop immediately if ALT or AST > 3× ULN or if any liver symptoms
Serum sodium	At initiation and during dose titration	Risk of hypernatraemia from aquaresis
Body weight, I/O	At initiation	Ensure patient is not becoming dehydrated
RFT	Every 3–6 months	Monitor ongoing GFR trajectory
TKV by MRI	Annually or per protocol	Assess treatment response

The dominant side effects are all consequences of V2 blockade → aquaresis:

Polyuria (often 4–6 L/day, sometimes more) — patients must have easy access to a toilet
Thirst and polydipsia — patients MUST drink freely; never restrict water
Nocturia — significant impact on quality of life; some patients take split dosing (higher morning dose, lower evening dose)
Hypernatraemia — if not drinking enough
Hepatotoxicity — idiosyncratic, unrelated to dose; monitor LFTs strictly

Tolvaptan Counselling Mnemonic: WATER

W = Water intake must be free and unrestricted A = ALT/AST monitoring monthly (liver injury risk) T = Toilet access must be available (massive polyuria) E = Effective contraception required (women) R = Regular follow-up for Na, RFT, TKV

B4. Management of Specific Complications

Pain is the most common reason ADPKD patients seek medical attention (~60% of patients) ^[1]. Causes include cyst enlargement (capsular stretching), cyst haemorrhage, cyst infection, and nephrolithiasis.

Approach	Detail	Rationale
Simple analgesia	Paracetamol (first-line)	Safe in CKD; avoid NSAIDs (nephrotoxic + reduce GFR via prostaglandin inhibition → afferent arteriolar vasoconstriction)
Avoid NSAIDs	Contraindicated	↓prostaglandins → ↓afferent arteriolar dilatation → ↓GFR; also ↑risk of AKI and GI bleeding; interfere with antihypertensive effect of ACEI/ARB
Weak opioids	Codeine, tramadol (short-term)	For moderate pain; avoid long-term use due to dependence and constipation
Cyst aspiration ± sclerotherapy	CT/USG-guided aspiration; inject sclerosant (ethanol/povidone-iodine)	For dominant symptomatic cysts causing focal pain. Aspiration alone has high recurrence (~80%); sclerotherapy reduces recurrence.
Laparoscopic cyst decortication (fenestration/deroofing)	Laparoscopic or open surgical unroofing of superficial cysts	For multiple symptomatic cysts; removes cyst wall to decompress. Provides temporary relief but cysts recur.
Nephrectomy	Should be avoided whenever possible in ADPKD ^[1]	Reserved as last resort. Most often considered for pain that is constant and requires narcotic medications or is associated with reduced QOL extending over prolonged periods of time. ^[1]

Indications for nephrectomy: ^[1]

Chronic pain
Chronic haematuria requiring transfusion
Recurrent cyst infections or UTI
Renal cell carcinoma (RCC)
Uncontrolled renal haemorrhage in patients contraindicated to or failure with intra-arterial embolization
Marked limitation of daily activities such as fatigue, anorexia and other signs of malnutrition

This is a particularly challenging complication because most antibiotics cannot penetrate the cyst wall effectively.

Aspect	Detail
Organisms	Usually Gram-negative enteric organisms (E. coli, Klebsiella, Proteus) from ascending UTI
Clinical features	Fever, flank pain/tenderness localized to a cyst; may not have LUTS; blood cultures often positive; urine culture may be NEGATIVE (if cyst does not communicate with collecting system)
Diagnosis	CT or MRI (thickened cyst wall, rim enhancement, gas within cyst); PET-CT or gallium scan for localization if needed; FDG-PET is the most sensitive for localizing infected cysts
Antibiotic choice	Lipid-soluble antibiotics against Gram-negative enteric organisms are preferred for cyst infection ^[1]
Duration	Requires 4–6 weeks of treatment ^[1]
Specific agents	Cotrimoxazole / Fluoroquinolones ^[1]
Why lipid-soluble?	Cyst walls are lined by epithelium with tight junctions → water-soluble antibiotics (e.g., aminoglycosides, beta-lactams) penetrate poorly into the cyst fluid. Lipid-soluble agents (fluoroquinolones, trimethoprim-sulfamethoxazole, chloramphenicol, metronidazole) cross the lipid bilayer of cyst epithelial cells and achieve adequate intracystic concentrations.
If medical therapy fails	CT-guided percutaneous cyst aspiration and drainage ± intracystic antibiotic instillation

Cyst Infection Pearl

If a patient with ADPKD has fever and flank pain but a NEGATIVE urine culture, think cyst infection — the infected cyst may not communicate with the collecting system. Blood cultures are more likely to be positive. CT or PET-CT can help localize the infected cyst.

Approach	Detail
Conservative (first-line)	Bedrest, hydration, and analgesics ^[1]. Most episodes are self-limiting (2–7 days). Avoid anticoagulants and antiplatelet agents during acute episode.
If persistent and severe	Percutaneous arterial embolization or nephrectomy ^[1] — these are last resorts for life-threatening haemorrhage that does not settle with conservative measures.
Avoid vigorous physical activity	During and for 2 weeks after episode to prevent recurrence

~20–30% of ADPKD patients develop stones, predominantly uric acid (due to low urinary pH and stasis) and calcium oxalate (due to low urinary citrate). ^[1]

Approach	Detail
Prevention	↑fluid intake (≥ 3 L/day), ↓sodium intake (< 2 g/day), potassium citrate supplementation (↑urinary citrate + ↑urinary pH for uric acid stones)
Acute management	Standard: analgesia (paracetamol, avoid NSAIDs), α-blocker (tamsulosin for MET if distal ureteric stone 5–10 mm) ^[15]
Definitive treatment	ESWL has ↓success rate in ADPKD (stones obscured by cysts on imaging; fragments trapped in distorted collecting system). Ureteroscopy or PCNL may be preferred depending on stone size and location. ^[15]

As ADPKD progresses, standard CKD management applies — this is identical to CKD from any cause:

Complication	Management	Detail
Anaemia	ESA (erythropoiesis-stimulating agents, e.g., Mircera) + IV iron	Start when Hb < 10 g/dL; target Hb 10–11.5 g/dL; ADPKD patients tend to have less severe anaemia than other CKD patients (cyst lining retains some EPO capacity) ^[14]
CKD-MBD	Phosphate binders, vitamin D analogues, calcimimetics	↓PO4 retention + ↓PTH + correct hypoCa; phosphate binders taken with meals ^[14]
Metabolic acidosis	Oral NaHCO₃ or citrate supplements	Target serum HCO₃⁻ 23–29 mmol/L; ↓bone resorption, ↓protein catabolism ^[14]
Hyperkalaemia	Dietary K restriction, sodium polystyrene sulfonate (Resonium), patiromer or SZC if recurrent	↓K excretion in CKD; monitor closely on ACEI/ARB ^[14]
Dyslipidaemia	Statins	Treatment of hyperlipidaemia in patients with ADPKD who have reduced renal function ^[1]; CKD is independent CVD risk factor ^[14]
CVD risk	Lifestyle + statins + BP control + aspirin (if indicated)	CKD confers significantly ↑CVD mortality ^[14]
Fluid overload	Salt restriction + loop diuretics (furosemide) ± thiazide (metolazone)	Only in later CKD when fluid retention occurs ^[14]

When ADPKD progresses to ESRD (eGFR < 10–15 or symptomatic uraemia), RRT is required. ^[1]^[14]

Modality	Suitability in ADPKD	Key Considerations
Haemodialysis (HD)	Generally preferred over PD in ADPKD	Standard vascular access (AV fistula preferred). Allow more control over dialysis parameters ^[14]
Peritoneal dialysis (PD)	Less commonly performed in ADPKD	Difficult for patients to accommodate large volumes of dialysate fluid in the setting of enlarged kidneys; increased risk of peritonitis secondary to cyst infection; and risk of abdominal hernia ^[1]. However, PD is still feasible in many ADPKD patients, especially if kidney size is moderate. In HK, the "PD-first" policy means PD is often tried first. ^[14]
Renal transplantation	Treatment of choice — offers best quality of life, survival, and is most cost-effective ^[1]^[14]	Patients with very large polycystic kidneys and recurrent renal cyst infection may require pre-transplant nephrectomy or bilateral nephrectomy to accommodate the allograft and reduce pain ^[1]. Patients should be screened for presence of intracranial aneurysm before surgery due to possible haemodynamic instability ^[1].

Timing of RRT initiation: ^[14]

Begin discussions at eGFR ~20–30 mL/min → allow preparation
Consider living donor pre-emptive transplantation if eGFR < 20 with evidence of progressive irreversible CKD over 6–12 months
Initiate RRT when symptomatic: uraemic serositis, uncontrollable volume/BP, progressive malnutrition, cognitive impairment

Indications for RRT in AKI (AEIOU): ^[14]

A = Acidosis (refractory metabolic acidosis pH < 7.1, HCO₃ < 10)
E = Electrolyte (hyperkalaemia > 6.5 refractory to medical Rx)
I = Intoxication
O = Overload (fluid overload refractory to diuretics)
U = Uraemia (pericarditis, encephalopathy)

B7. Management of Extrarenal Manifestations

Ruptured cerebral aneurysm resulting in subarachnoid or intracerebral haemorrhage is the MOST serious complication of PKD. ^[1]

Aspect	Detail
Screening	CTA or MRA is offered to high-risk patients: those with previous rupture, positive family history of aneurysm, high occupational risk, and patients requiring chronic anticoagulation ^[1]
Small asymptomatic aneurysm < 7 mm (Asian < 5 mm)	Generally requires observation only without intervention due to low risk of haemorrhage ^[1]
Asymptomatic aneurysm ≥ 7–10 mm (Asian ≥ 5 mm)	Warrants strong consideration for treatment taking into account patient's age, existing medical and neurological conditions, and risks of treatment ^[1]
Large symptomatic aneurysm	Requires treatment and is cost-effective ^[1]
Treatment options	Microsurgical clipping or endovascular coiling/stenting (same as for aneurysms in non-ADPKD patients)

Approach	Indication
Observation	Asymptomatic (most patients) — liver function is typically preserved even with massive cysts
Cyst aspiration + sclerotherapy	Dominant symptomatic cyst
Fenestration (laparoscopic or open)	Multiple symptomatic superficial cysts
Hepatic resection	Massive cystic disease confined to one lobe with preserved contralateral liver
Liver transplantation	Severe PLD with incapacitating symptoms, malnutrition, or combined liver-kidney transplant in ESRD
Somatostatin analogues (octreotide/lanreotide)	Reduces hepatic cyst growth in RCTs; reduces liver volume by 3–6% over 6–12 months; considered for patients with severe PLD not amenable to surgery
Avoid oestrogens	OCP and HRT exacerbate hepatic cyst growth (hepatic cysts have oestrogen receptors)

MOST common abnormalities include MVP and aortic regurgitation (AR). Less frequent lesions include tricuspid valve prolapse (TVP), MR and TR. ^[1]

Approach	Detail
Echocardiographic surveillance	Baseline + as clinically indicated
Endocarditis prophylaxis	Standard indications (generally NOT required for MVP without regurgitation in current guidelines)
Valve surgery	Only if haemodynamically significant (severe MR, severe AR with LV dilatation)

Stage	eGFR	Key Interventions
At-risk (pre-symptomatic)	Normal	Genetic counselling, screening USG, lifestyle advice, avoid nephrotoxins
Early ADPKD	> 60	Intensive BP control (< 110/75 if young), ACEI/ARB, lifestyle, assess for tolvaptan eligibility (Mayo 1C–1E), ICA screening if FHx
Moderate CKD	30–60	Tolvaptan if eligible, ACEI/ARB, manage CKD complications (anaemia, CKD-MBD), statin, less aggressive BP target (< 140/90)
Advanced CKD	15–30	Continue above, begin RRT planning, referral to nephrologist, consider pre-emptive transplant evaluation
ESRD	< 10–15	RRT: HD (preferred over PD in ADPKD), transplantation (treatment of choice). Pre-transplant nephrectomy if indicated. Screen for ICA before transplant.

High Yield Summary — Management of ADPKD

Non-pharmacological: Na restriction < 2 g/day, ↑fluid intake (suppresses vasopressin → ↓cAMP → ↓cyst growth), avoid caffeine, exercise, weight control.
BP control: ACEI first-line (RAAS-driven HTN); target < 110/75 in young patients with eGFR > 60 (HALT-PKD); < 140/90 in moderate-advanced CKD (avoid hypoperfusion).
Tolvaptan: V2 receptor antagonist, the only disease-modifying therapy. Slows TKV growth and GFR decline. For rapidly progressive disease (Mayo 1C-1E). Main side effects: polyuria, hepatotoxicity. Monitor LFTs monthly × 18 months.
Cyst infection: lipid-soluble antibiotics (fluoroquinolones/cotrimoxazole) × 4–6 weeks (because water-soluble drugs cannot penetrate cyst wall).
Pain: paracetamol first; AVOID NSAIDs; cyst aspiration ± sclerotherapy; nephrectomy as last resort.
Nephrolithiasis: primarily uric acid and calcium oxalate stones; ↑fluids, potassium citrate, standard surgical options.
RRT: HD preferred over PD (enlarged kidneys limit PD); transplantation is treatment of choice. Pre-transplant nephrectomy may be needed. Screen for ICA before transplant.
ICA: most serious complication. Screen high-risk patients with MRA. Small < 5 mm (Asian): observe. ≥ 5 mm: consider intervention.
Statins for dyslipidaemia in CKD; standard CKD-MBD and anaemia management as eGFR declines.

Active Recall - Management of ADPKD

References

^[1] Senior notes: felixlai.md (Polycystic kidney disease — Treatment and Complications sections) ^[3] Senior notes: Ryan Ho Cardiology.pdf (p.179–180 — Hypertension management, BP targets, antihypertensive choice) ^[14] Senior notes: Ryan Ho Urogenital.pdf (p.99, 104, 106, 109, 111 — CKD management: prevention of progression, BP control, anaemia, metabolic acidosis, CVD risk, RRT) ^[15] Senior notes: Ryan Ho Urogenital.pdf (p.141 — Stone management: conservative, MET, definitive)

Complications of ADPKD

Before diving into individual complications, let's be clear about what ultimately happens to ADPKD patients. Most patients die from cardiac causes — cardiac hypertrophy and coronary disease accounts for the majority of cases. ^[1] This is critical to internalise: ADPKD is not just a kidney disease — it is a systemic cardiovascular disease driven by decades of hypertension, CKD-related atherogenesis, and the direct effects of polycystin dysfunction on vascular tissue.

The complications can be organised into three categories:

Renal complications — direct consequences of cyst growth within the kidneys
Extrarenal complications — consequences of polycystin dysfunction in non-renal tissues
Cyst-specific complications — acute events related to individual cysts

The second most common cause of death in patients with ADPKD is infected renal cysts and pyelonephritis. ^[1]

A. Renal Complications

Aspect	Detail
Prevalence	~50% of ADPKD patients reach ESRD by age 60 (PKD1) or ~75 years (PKD2)
Mechanism	Progressive cyst enlargement → compression + ischaemia of normal nephrons → tubular atrophy + interstitial fibrosis → compensatory hyperfiltration of remaining nephrons → secondary glomerulosclerosis → further nephron loss → eventual failure of all compensatory mechanisms → GFR < 10–15 → uraemia ^[14]
Why GFR is preserved for so long	Only 1–5% of nephrons develop cysts (two-hit hypothesis). The remaining 95–99% of nephrons compensate through hyperfiltration. GFR remains normal until TKV exceeds ~1500 mL (normal ~300 mL total). Once the compensatory reserve is exhausted, GFR drops relatively rapidly at ~4.4–5.9 mL/min/year.
Management	Requires renal replacement therapy such as haemodialysis or renal transplantation ^[1]
Clinical features of ESRD	Standard uraemic symptoms: fatigue, anorexia, nausea, pruritus, cognitive impairment, peripheral neuropathy, pericarditis, bleeding diathesis. Fluid overload: oedema, dyspnoea, pulmonary oedema. Electrolyte disturbances: hyperkalaemia, metabolic acidosis. ^[14]

High Yield: The natural history of ADPKD follows a predictable trajectory — years of preserved GFR with rising TKV, then a relatively rapid decline phase. The inflection point typically occurs in the 4th–5th decade for PKD1.

Aspect	Detail
Prevalence	Occurs in up to 25% of patients ^[1]
Stone composition	Most stones are composed of uric acid, and the remaining are calcium oxalate ^[1]
Mechanism (from first principles)	Three factors conspire to create stones in ADPKD: (1) Urinary stasis — distorted, compressed collecting system and calyces create pockets of static urine where crystals nucleate; (2) Low urinary citrate (hypocitraturia) — tubular dysfunction impairs citrate reabsorption/secretion; citrate normally inhibits calcium stone formation by chelating calcium; (3) Low urinary pH — tubular dysfunction impairs ammonia excretion, leading to relatively acidic urine → favours uric acid crystal precipitation
Clinical features	Renal colic (flank pain radiating to groin), haematuria. However, stones are often difficult to detect on imaging because they may be obscured by surrounding cysts.
Diagnosis	NCCT is the investigation of choice, but stones within cysts may be missed. MRI can distinguish stones from cyst wall calcification.
Management	Prevention: ↑fluid intake, potassium citrate supplementation (↑pH dissolves uric acid stones, ↑citrate chelates calcium). Treatment: ESWL has reduced efficacy in ADPKD (cysts obscure targeting, fragments trapped in distorted collecting system); ureteroscopy or PCNL may be preferred.

This deserves special emphasis because it is both common and uniquely difficult to manage in ADPKD.

Aspect	Detail
Significance	Second most common cause of death in patients with ADPKD ^[1]
Pathophysiology	Correlates with the structural abnormality of the renal parenchyma ^[1] — distorted collecting system → urinary stasis → ascending infection. Cyst fluid is protein-rich and glucose-rich → excellent growth medium for bacteria.
Typical organisms	Gram-negative enterics: E. coli (most common), Klebsiella, Proteus, Enterobacter
Clinical features	Fever, flank pain localised to one area, systemic sepsis. Important: urine culture may be NEGATIVE if the infected cyst does not communicate with the collecting system. Blood cultures are more sensitive.
Diagnosis	CT (rim-enhancing cyst, wall thickening, intracystic debris); FDG-PET CT is the most sensitive for localising the infected cyst (infected cysts show high FDG uptake due to metabolically active neutrophils)
Treatment	Lipid-soluble antibiotics (fluoroquinolones, cotrimoxazole) for 4–6 weeks ^[1]. If refractory: CT-guided percutaneous drainage. If recurrent/refractory: consider nephrectomy.
Risk factors	Female sex (shorter urethra → ascending infection), urinary stasis, instrumentation (catheterisation, cystoscopy), immunosuppression (post-transplant)
Imaging indication	Polycystic kidney disease with poor renal function is listed as an indication for imaging in the setting of pyelonephritis ^[16]

Cyst Infection vs Simple UTI

A common exam trap: in ADPKD, standard UTI treatment with beta-lactams (amoxicillin, cephalosporins) often fails because these water-soluble drugs cannot penetrate the cyst wall. Always use lipid-soluble antibiotics for suspected cyst infection. If a patient with ADPKD has persistent fever despite "appropriate" antibiotics, consider that they have a cyst infection rather than simple pyelonephritis, and switch to fluoroquinolones or cotrimoxazole for a prolonged course.

Aspect	Detail
Presentation	Presents with haematuria ^[1] — gross haematuria occurs in 35–50% of ADPKD patients. Also causes acute severe flank pain from sudden cyst distension or rupture with perinephric blood.
Mechanism	Cyst walls contain fragile, thin-walled blood vessels (neovascularisation). Stretching of the cyst wall as it expands → vessel rupture → bleeding into the cyst lumen. If the cyst communicates with the collecting system → gross haematuria. If the cyst ruptures → perinephric haematoma → severe flank/back pain.
Triggers	Physical trauma (especially contact sports), heavy lifting, anticoagulation therapy, hypertension
Natural history	Most episodes are self-limiting (2–7 days). Haematuria that persists > 1 week or is associated with haemodynamic instability requires further evaluation.
Management	Conservative (bedrest, hydration, analgesia with paracetamol — avoid NSAIDs). Avoid anticoagulants and antiplatelet agents during the acute episode. If persistent and severe: angiographic embolisation. Nephrectomy as last resort for life-threatening haemorrhage.

B. Extrarenal Complications

This is where ADPKD shows its true nature as a systemic ciliopathy. Polycystin-1 and polycystin-2 are expressed in many tissues beyond the kidney.

Aspect	Detail
Epidemiology	Present in the majority of patients who have normal renal function and have reached the 40s ^[1]
Timing	Occurs early prior to loss of kidney function (reduction in GFR) ^[1] — this is a hallmark that distinguishes ADPKD from most other causes of CKD where hypertension is a late consequence.
Mechanism	Result from increased activation of RAAS or increased sympathetic nerve activity ^[1]. Expanding cysts compress intrarenal vasculature → regional ischaemia → juxtaglomerular cells secrete renin → angiotensin II → vasoconstriction + aldosterone → Na/water retention → ↑BP. Additionally, sympathetic nervous system overactivation contributes (mechanism less clear, likely related to renal afferent signalling).
Significance	Risk factor for both cardiovascular and kidney disease progression in ADPKD ^[1]. Chronic hypertension → LVH → diastolic dysfunction → heart failure. Also accelerates atherosclerosis → coronary artery disease, stroke. Contributes to faster GFR decline via glomerular injury.
Target organ damage from HTN	LVH, coronary artery disease, cerebrovascular disease, hypertensive retinopathy, aortic disease. ^[3]
Management	ACEI/ARB first-line, BP targets as discussed in management section

High Yield: Hypertension in ADPKD is RAAS-driven, which is why ACEI/ARB are the first-line agents — they directly target the pathophysiology. However, the hypertension also has a volume-expansion component, which is why sodium restriction is equally important.

B2. Cerebral (Intracranial) Aneurysms — The Most Serious Complication

Aspect	Detail
Prevalence	~8–12% in ADPKD (vs 2–5% in the general population) ^[17]
Significance	Ruptured cerebral aneurysm resulting in subarachnoid or intracerebral haemorrhage is the MOST serious complication of PKD ^[1]
Location	Commonly Circle of Willis ^[17]; 90% anterior circulation ^[17] — particularly anterior communicating artery, posterior communicating artery, and middle cerebral artery bifurcation
Mechanism	Polycystin-1 and polycystin-2 are expressed in vascular smooth muscle cells and endothelium. Their dysfunction leads to weakening of the arterial wall, especially at bifurcation points where haemodynamic stress is maximal → saccular (berry) aneurysm formation. Co-existing hypertension further increases haemodynamic wall stress.
Predisposing factors for aneurysm	Smoking, hypertension, age > 40, family history, female sex, CTD: Ehlers-Danlos syndrome, AD polycystic kidney disease, Marfan syndrome, fibromuscular dysplasia ^[17]
Natural history	Can be forever asymptomatic with unpredictable spontaneous rupture ^[17]

Feature	Detail
Thunderclap headache	"Worst headache of my life," sudden onset, maximal at onset. Due to blood irritating meninges.
Meningism	Neck stiffness, photophobia, Kernig's sign — due to blood in subarachnoid space irritating meninges
Loss of consciousness	From sudden ↑ICP; may be transient or persistent depending on severity
"Surgical" CN III palsy	Non-pupil-sparing CN III palsy (ptosis, "down and out" eye, fixed dilated pupil) — classical for posterior communicating artery aneurysm compressing CN III ^[17]
Focal neurological deficits	Depend on location of aneurysm and any associated intracerebral haemorrhage or vasospasm

Feature	Detail
Asymptomatic	Most unruptured aneurysms — detected incidentally or on screening
Mass effect	Large aneurysms may compress adjacent structures: CN III palsy (PComA), visual loss (ophthalmic artery) ^[17]
Thromboembolism	Aneurysm predisposes to intraluminal thrombus formation → distal embolisation ^[17]

Scenario	Approach
Screening offered to high-risk patients	Those with previous rupture, positive family history of aneurysm, high occupational risk, and patients requiring chronic anticoagulation ^[1]
Screening modality	MRA (preferred) or CTA. CTA or MRA is offered ^[1]
Asymptomatic small aneurysm < 7 mm (Asian < 5 mm)	Generally requires observation only without intervention due to low risk of haemorrhage ^[1]
Asymptomatic aneurysm ≥ 7–10 mm (Asian ≥ 5 mm)	Warrants strong consideration for treatment, taking into account patient's age, existing medical and neurological conditions, and risks of treatment ^[1]
Large symptomatic aneurysm	Requires treatment and is cost-effective ^[1]
Treatment options	Microsurgical clipping (apply clip at neck of aneurysm) or endovascular coiling/stenting (detachable coil or flow diverter placed via catheter) ^[17]

Asian-Specific Threshold

Note the lower intervention threshold for Asian patients (≥ 5 mm vs ≥ 7 mm for non-Asians). This is based on data showing that Asian populations have a higher rupture rate for small aneurysms compared to Western populations. This is highly relevant for Hong Kong practice. ^[1]

Aspect	Detail
Most common abnormalities	MVP (mitral valve prolapse) and AR (aortic regurgitation) ^[1]
Less frequent lesions	Tricuspid valve prolapse (TVP), MR (mitral regurgitation), and TR (tricuspid regurgitation) ^[1]
Prevalence	MVP occurs in ~25% of ADPKD patients (vs ~2–3% general population)
Mechanism	Polycystin dysfunction in cardiac valve connective tissue → myxomatous degeneration → redundant, prolapsing valve leaflets. Similar to how polycystin dysfunction weakens arterial walls (aneurysms) and colonic walls (diverticula).
Detection	Murmurs may not be audible but only demonstrated on echocardiogram ^[1]
Natural history	Majority of patients are asymptomatic but some may progress and require valve replacement ^[1]
Clinical significance	Most cases are benign. However, MVP with significant MR can lead to heart failure, atrial fibrillation, and rarely, sudden cardiac death. AR can progress if aortic root dilates.

Aspect	Detail
Status	Liver cyst derived from biliary epithelium is the MOST common extrarenal complication ^[1]
Prevalence	~83% by age 30–40; nearly universal in older patients
Gender difference	Massive cysts occur almost exclusively in women, particularly those who have had several pregnancies ^[1] — because hepatic cysts express oestrogen and progesterone receptors; oestrogen stimulates cyst epithelial proliferation and fluid secretion
Mechanism	Same ciliopathy mechanism in biliary epithelial cells. Defective polycystin → ↑cAMP → ↑fluid secretion via CFTR + cell proliferation → biliary cyst formation and expansion.
Key clinical distinction	Liver function is typically PRESERVED even with massive hepatomegaly — this is fundamentally different from ARPKD (where congenital hepatic fibrosis causes portal hypertension and synthetic dysfunction). The cysts replace liver volume but do not destroy hepatocytes.

Important distinction from ADPLD: ^[1]

Polycystic liver disease associated with ADPKD is different from autosomal dominant polycystic liver disease (ADPLD)
ADPLD has no or only a few renal cysts and does not progress to renal failure
ADPLD is caused by mutation in at least 2 distinct genes (PRKCSH and SEC63) ^[1]

Complication of PLD	Mechanism
Abdominal distension and early satiety	Mass effect from massive hepatomegaly
Pain	Capsular stretching, cyst haemorrhage, cyst infection
Hepatic venous outflow obstruction (rare)	Very large cysts compress hepatic veins → Budd-Chiari-like picture
Bile duct compression (rare)	Large cysts compress intrahepatic bile ducts → obstructive jaundice
Cyst infection	Ascending from biliary tree; presents with fever and RUQ pain
Malnutrition	Chronic early satiety from massive hepatomegaly

Occurs in 7–10% of patients with ADPKD. ^[1]

Usually asymptomatic and clinically insignificant
Same ciliopathy mechanism in pancreatic duct epithelium
Rarely cause pancreatitis
Important to distinguish from pancreatic cystic neoplasms (mucinous cystic neoplasm, IPMN) on imaging — ADPKD cysts are simple and benign

Colonic diverticula are found in many ADPKD patients on maintenance dialysis but may not occur in those without ESRD. ^[1]

Aspect	Detail
Mechanism	Connective tissue weakness in the colonic wall from polycystin dysfunction + chronic constipation in CKD/dialysis patients + increased intra-abdominal pressure from massive kidneys
Significance	Increased risk of diverticulitis and, critically, colonic perforation — especially in immunosuppressed post-transplant patients. Colonic perforation carries extremely high mortality in dialysis/transplant patients.
Management	High-fibre diet (prevention), prompt treatment of diverticulitis, low threshold for surgical consultation if perforation suspected in immunosuppressed patients

Both abdominal wall and inguinal hernias are found with increased frequency in ADPKD patients. ^[1]

Mechanism: Two factors combine:

Connective tissue weakness from polycystin dysfunction (same mechanism as diverticula, valve prolapse, and aneurysms)
Chronic increased intra-abdominal pressure from massively enlarged kidneys and liver

C. Complications of the Cysts Themselves

These are acute events that can occur at any time during the disease course:

Already discussed in detail above (Section A3). Key points reiterated:

Second most common cause of death in patients with ADPKD ^[1]
Lipid-soluble antibiotics essential (fluoroquinolones, cotrimoxazole)
4–6 weeks treatment duration
May need percutaneous drainage or nephrectomy if refractory

Presents with haematuria. ^[1]

Already discussed in Section A4. Usually self-limiting but can be dramatic and frightening for patients.

Let me tie this all together. Why do ADPKD patients die of cardiovascular disease?

Factor	Detail
Most common cause of death	Cardiac causes — cardiac hypertrophy and coronary disease ^[1]
Second most common cause of death	Infected renal cysts and pyelonephritis ^[1]
Most serious complication	Ruptured cerebral aneurysm ^[1]
Median age at ESRD	PKD1: ~54 years; PKD2: ~74 years
Factors predicting worse prognosis	PKD1 truncating mutation, male sex, early-onset hypertension (< 35y), gross haematuria before 30, large TKV (Mayo 1D–1E), early-onset symptoms
10-year survival on dialysis	Similar to other CKD causes; better outcomes post-transplant
Post-transplant outcomes	Excellent — similar or slightly better than non-ADPKD transplant recipients (because ADPKD patients tend to be younger and have fewer comorbidities than diabetic CKD patients)

Complication	Prevalence	Mechanism	Management
ESRD	~50% by age 60 (PKD1)	Cyst compression → nephron loss → fibrosis	RRT (HD, transplant)
Nephrolithiasis	~25%	Stasis, ↓citrate, ↓pH	↑fluids, K-citrate, ureteroscopy
Cyst infection	Common, esp. females	Stasis + ascending infection	Lipid-soluble Abx × 4–6 weeks
Cyst haemorrhage	35–50% (gross haematuria)	Fragile cyst wall vessels rupture	Conservative; embolisation if severe
Hypertension	~60% before GFR decline	RAAS activation from cyst compression	ACEI/ARB
Cerebral aneurysm	8–12%	Polycystin defect in vessel wall	Screen high-risk; clip/coil if indicated
MVP/AR	~25% / ~8%	Myxomatous valve degeneration	Echo surveillance; surgery if severe
Liver cysts	~83% by age 40	Ciliopathy in biliary epithelium	Observation; aspiration/surgery if severe
Pancreatic cysts	7–10%	Ciliopathy in pancreatic ducts	Usually observation
Colonic diverticula	↑ in dialysis pts	Connective tissue weakness + ↑IAP	High fibre; prompt Mx of diverticulitis
Hernias	Increased frequency	CT weakness + ↑IAP	Surgical repair if symptomatic

High Yield Summary — Complications of ADPKD

Most patients die from cardiac causes — LVH and coronary disease from decades of hypertension and CKD-related CVD risk.
Infected renal cysts/pyelonephritis is the second most common cause of death — must use lipid-soluble antibiotics for 4–6 weeks.
Ruptured cerebral aneurysm (SAH) is the MOST serious complication — prevalence 8–12%; screen high-risk patients with MRA; Asian threshold for intervention ≥ 5 mm.
Hypertension occurs EARLY (before GFR decline) due to RAAS activation from cyst compression of renal vasculature.
Nephrolithiasis in ~25% — predominantly uric acid and calcium oxalate; driven by stasis, low citrate, low pH.
Liver cysts are the most common extrarenal complication — oestrogen-dependent (worse in multiparous women); liver function preserved.
Cardiac valve disease: MVP and AR most common; usually asymptomatic; murmurs may only be detected on echocardiography.
Colonic diverticula and hernias: connective tissue weakness + increased intra-abdominal pressure; risk of perforation post-transplant under immunosuppression.
ADPLD (autosomal dominant polycystic liver disease) is a different condition from PLD associated with ADPKD — different genes, no renal failure.

Active Recall - Complications of ADPKD

References

^[1] Senior notes: felixlai.md (Polycystic kidney disease — Complications and Prognosis sections) ^[3] Senior notes: Ryan Ho Cardiology.pdf (p.177–178 — Secondary hypertension and target organ damage) ^[5] Senior notes: maxim.md (RCC risk factors including PKD; Polycystic liver disease section) ^[14] Senior notes: Ryan Ho Urogenital.pdf (p.99–100, 105, 109, 111 — CKD complications, cardiovascular morbidity, RRT) ^[16] Senior notes: Ryan Ho Urogenital.pdf (p.127 — Indications for imaging in pyelonephritis including PKD) ^[17] Lecture slides: GC 109. Headache and loss of consciousness Acute stroke, subarachnoid haemorrhage and vascular malformation.pdf (p.14, slides 27–28 — Cerebral aneurysm predisposing factors, SAH)

High Yield Summary

Polycystic Kidney Disease — Key Points for Exams:

ADPKD is the most common inherited kidney disease (1 in 400–1000). Autosomal dominant. PKD1 (85%, chromosome 16, worse) vs PKD2 (15%, chromosome 4, milder).
Pathophysiology: ciliopathy → dysfunctional polycystin-1/2 complex on primary cilium → ↓Ca²⁺ influx → ↑cAMP → fluid secretion (CFTR) and cell proliferation (Ras/MAPK, mTOR) → cyst growth.
Two-hit hypothesis: germline mutation + somatic second hit → explains why only 1–5% of nephrons form cysts.
Clinical presentation: flank pain, haematuria, hypertension (early, RAAS-mediated), UTIs, renal stones, bilateral palpable kidneys. Polyuria/nocturia from concentrating defect.
Extrarenal: hepatic cysts (most common), cerebral aneurysms (8–12%) ^[3], MVP, colonic diverticula.
Hypertension occurs early (60% before GFR decline) due to intrarenal RAAS activation from cyst compression of vasculature.
ARPKD: PKHD1 gene, collecting duct cysts, congenital hepatic fibrosis, presents perinatally.
Tolvaptan (V2 receptor antagonist) works by ↓cAMP in collecting duct cells → slows cyst growth.
Screening: first-degree relatives with renal ultrasound; cerebral aneurysm screening with MRA for high-risk patients (FHx of aneurysm/SAH).
ADPKD is a predisposing factor for cerebral aneurysm and SAH ^[3], and acquired cystic kidney disease (from chronic dialysis) is a risk factor for RCC ^[4]^[5].

High Yield Summary — Differential Diagnosis of PKD

The most common DDx for ADPKD is multiple benign simple cysts — distinguished by age (simple cysts rare < 30y), kidney size (normal in simple cysts), and absence of FHx/extrarenal features.
Acquired cystic kidney disease occurs in chronic dialysis patients — kidneys are small/normal (not enlarged), no FHx, no extrarenal cysts, but carries 30× RCC risk requiring yearly USG surveillance.
Key genetic DDx: TSC (AMLs, skin lesions, seizures), VHL (haemangioblastomas, RCC, phaeochromocytoma), HNF1B (MODY5 + cysts).
Medullary sponge kidney: medullary-only cysts, normal-sized kidneys, presents with stones/nephrocalcinosis.
ARPKD: collecting duct cysts + congenital hepatic fibrosis, presents perinatally.
For bilateral palpable kidneys: most common cause is ADPKD; also consider diabetic nephropathy (early), amyloidosis, lymphoma, bilateral hydronephrosis.
ADPKD is an important cause of secondary hypertension in young patients — screen with renal USG.

High Yield Summary — Diagnosis of ADPKD

Diagnosis is clinical + imaging: Renal USG is first-line. Apply age-specific Pei-Ravine criteria in patients with positive FHx. In patients without FHx, ≥ 10 cysts per kidney + enlarged kidneys + no alternative diagnosis strongly suggests ADPKD.
USG is less sensitive for PKD2 due to late-onset cystogenesis → consider MRI or direct genetic testing.
Genetic testing is indicated for equivocal imaging, very young patients, potential kidney donors, and when definitive diagnosis is required. ^[1]
Proteinuria is NOT a major feature of ADPKD — if heavy proteinuria is present, suspect superimposed glomerulopathy. ^[1]
Renal function usually remains normal until the 40s — normal RFT does NOT exclude ADPKD. ^[1]
MRI is the gold standard for TKV measurement → Mayo classification (1A–1E) → determines tolvaptan eligibility.
MRA/CTA brain is the initial test for intracranial aneurysm screening in high-risk patients (FHx of aneurysm/SAH). ^[1]
Risk stratification: Mayo classification (htTKV), PROPKD score (genotype + clinical), eGFR trajectory.
CBC may show anaemia (CKD or haematuria) or erythrocytosis (compensatory EPO production). ^[1]

High Yield Summary — Management of ADPKD

Non-pharmacological: Na restriction < 2 g/day, ↑fluid intake (suppresses vasopressin → ↓cAMP → ↓cyst growth), avoid caffeine, exercise, weight control.
BP control: ACEI first-line (RAAS-driven HTN); target < 110/75 in young patients with eGFR > 60 (HALT-PKD); < 140/90 in moderate-advanced CKD (avoid hypoperfusion).
Tolvaptan: V2 receptor antagonist, the only disease-modifying therapy. Slows TKV growth and GFR decline. For rapidly progressive disease (Mayo 1C-1E). Main side effects: polyuria, hepatotoxicity. Monitor LFTs monthly × 18 months.
Cyst infection: lipid-soluble antibiotics (fluoroquinolones/cotrimoxazole) × 4–6 weeks (because water-soluble drugs cannot penetrate cyst wall).
Pain: paracetamol first; AVOID NSAIDs; cyst aspiration ± sclerotherapy; nephrectomy as last resort.
Nephrolithiasis: primarily uric acid and calcium oxalate stones; ↑fluids, potassium citrate, standard surgical options.
RRT: HD preferred over PD (enlarged kidneys limit PD); transplantation is treatment of choice. Pre-transplant nephrectomy may be needed. Screen for ICA before transplant.
ICA: most serious complication. Screen high-risk patients with MRA. Small < 5 mm (Asian): observe. ≥ 5 mm: consider intervention.
Statins for dyslipidaemia in CKD; standard CKD-MBD and anaemia management as eGFR declines.

High Yield Summary — Complications of ADPKD

Most patients die from cardiac causes — LVH and coronary disease from decades of hypertension and CKD-related CVD risk.
Infected renal cysts/pyelonephritis is the second most common cause of death — must use lipid-soluble antibiotics for 4–6 weeks.
Ruptured cerebral aneurysm (SAH) is the MOST serious complication — prevalence 8–12%; screen high-risk patients with MRA; Asian threshold for intervention ≥ 5 mm.
Hypertension occurs EARLY (before GFR decline) due to RAAS activation from cyst compression of renal vasculature.
Nephrolithiasis in ~25% — predominantly uric acid and calcium oxalate; driven by stasis, low citrate, low pH.
Liver cysts are the most common extrarenal complication — oestrogen-dependent (worse in multiparous women); liver function preserved.
Cardiac valve disease: MVP and AR most common; usually asymptomatic; murmurs may only be detected on echocardiography.
Colonic diverticula and hernias: connective tissue weakness + increased intra-abdominal pressure; risk of perforation post-transplant under immunosuppression.
ADPLD (autosomal dominant polycystic liver disease) is a different condition from PLD associated with ADPKD — different genes, no renal failure.

Polycystic Kidney Disease

1. Definition

2. Epidemiology

ADPKD

ARPKD

3. Risk Factors

4. Anatomy and Function (Relevant Normal Kidney Anatomy)

Normal Kidney Structure

Why This Matters in PKD

Relevant Extrarenal Anatomy

5. Etiology and Pathophysiology

5.1 Genetic Basis

ADPKD (Autosomal Dominant)

ARPKD (Autosomal Recessive)

5.2 Pathophysiology — The Ciliopathy Model

What Is the Primary Cilium?

The Polycystin-1/Polycystin-2 Complex

What Happens When the Complex Fails (in PKD)?

5.3 Cyst Growth and Renal Consequences

5.4 Pathophysiology of Hypertension in ADPKD

5.5 Pathophysiology of Extrarenal Manifestations

6. Classification

6.1 By Inheritance Pattern

6.2 ADPKD by Genotype

6.3 Mayo Classification (for Risk Stratification)

7. Clinical Features

7.1 Symptoms

Renal Symptoms

Symptoms from Extrarenal Manifestations

Symptoms from CKD Progression (Late)

7.2 Signs

General Inspection

Abdominal Examination

Cardiovascular Examination

Other Signs

Neurological Signs (If Complications)

8. Pathophysiology Summary Diagram

9. Key Differences: ADPKD vs ARPKD (Summary Table)

Active Recall - Polycystic Kidney Disease (Pre-DDx/Dx/Mx)

References

Overview: What Are We Differentiating?

A. Differential Diagnosis of Multiple Renal Cysts

Mermaid Diagnostic Approach

1. Multiple Benign Simple Cysts

2. Acquired Renal Cystic Disease (ARCD / ACKD)

3. Localized (Unilateral) Renal Cystic Disease

4. Medullary Sponge Kidney (MSK)

5. Genetic Syndromic Conditions with Renal Cysts

a) Tuberous Sclerosis Complex (TSC)

b) Von Hippel-Lindau Disease (VHL)

c) HNF1B-Associated Kidney Disease (Formerly RCAD — Renal Cysts and Diabetes)

d) Oral-Facial-Digital Syndrome Type 1 (OFD1)

6. Autosomal Recessive Polycystic Kidney Disease (ARPKD)

7. Nephronophthisis (NPHP) and Medullary Cystic Kidney Disease (MCKD)

B. Differential Diagnosis of Bilateral Palpable Kidneys

C. Differential Diagnosis by Presenting Feature

Presenting with Haematuria

Presenting with Hypertension in a Young Patient

D. Summary: Key Differentiating Features at a Glance

Active Recall - Differential Diagnosis of PKD

Overview: The Diagnostic Philosophy

A. Diagnostic Criteria

A1. Patients WITH a Positive Family History of ADPKD

Unified Pei-Ravine USG Criteria (2009) — For Patients with Known PKD1 Mutation

For Patients with Unknown Genotype or Known PKD2 Mutation

A2. Patients WITHOUT a Family History of ADPKD (De Novo or Unknown FHx)

A3. MRI/CT-Based Criteria

A4. Genetic Testing Criteria

B. Diagnostic Algorithm

C. Investigation Modalities

C1. History and Physical Examination

C2. Biochemical Investigations

C3. Radiological Investigations

Renal Ultrasound (USG) — First-Line Imaging

CT Scan (With or Without Contrast)

MRI (T1-Weighted and T2-Weighted)

Other Imaging

C4. Genetic Testing

C5. Screening for Extrarenal Complications

C6. Prognostic Assessment / Risk Stratification